The effects of age and L-DOPA replacement on locomotor deficits in the AS/AGU mutant rat by Russell, David
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
The Effects of Age and L DOPA Replacement On 
Locomotor Deficits in the AS/AGU Mutant Rat
David Russell
Thesis submitted for the degree of Master of Medical Science in the Faculty of
Medicine
Laboratory of Human Anatomy 
Glasgow University
May 2001
ProQuest N um ber: 10645959
All rights reserved
INFORMATION TO ALL USERS 
The qua lity  of this reproduction  is d e p e n d e n t upon the qua lity  of the copy subm itted.
In the unlikely e ve n t that the au tho r did not send a co m p le te  m anuscrip t 
and there are missing pages, these will be no ted . Also, if m ateria l had to be rem oved,
a no te  will ind ica te  the de le tion .
uesL
ProQuest 10645959
Published by ProQuest LLO (2017). C opyrigh t of the Dissertation is held by the Author.
All rights reserved.
This work is protected aga inst unauthorized copying under Title 17, United States C o de
M icroform  Edition © ProQuest LLO.
ProQuest LLO.
789 East Eisenhower Parkway 
P.Q. Box 1346 
Ann Arbor, Ml 4 81 06 - 1346
ACKNOWLEDGEMENTS
I have pleasure in expressing my sincere gratitude to Professor Tony Payne, Professor of 
Anatomy at Glasgow University, who was my supervisor during this study. His knowledge 
and guidance throughout were inspirational.
I am most grateful to Dr Jackie Campbell for her support, encouragement and 
constructive criticism, all offered with great willingness and humour, and also to Dr Des 
Gilmore for his guidance and support.
My grateful thanks to Mr Matt Neilson for his help and knowledge in Image 
Analysis techniques. I extend my thanks to Mr N.K. Bennett and his staff for their technical 
assistance, also to my colleagues in the Laboratory of Human Anatomy, Mr Jimmy 
McGadey, Mr Andy Lockhart, Mr Gordon Reford, Mr Iain Sim and Ms Caroline Morris.
I am especially grateful to my wife Tracy, and my daughter Becky for their 
patience, understanding and encouragement throughout the teim of study.
Finally, to anyone that I have forgotten to mention -  thank you.
TABLE OF CONTENTS
Chapter Page
1. Introduction i
1.1. The Basal Ganglia 1
1.1.1. Components of the Basal Ganglia 1
1.1.2. Striatum 2
1.1.3. Globus Pallidus 3
1.1.4. Substantia Nigra 3
1.1.5. Subthalamic Nucleus 4
1.1.6. Compartmental Organisation of the Striatum 4
1.1.7. Parallel Organisation of Cortico-Basal Ganglia Loops 6
1.1.8. The Motor Circuit 7
1.1.9. The Dopaminergic System 10
1.1.10. Dopamine Receptors in the Striatum 12
1.1.11. The 6 “Hydroxydopamine Model 13
1.2. Movement Disorders 14
1.2.1. Multiple System Atrophy 14
1.2.2. Supranuclear Palsy 15
1.2.3. Corticobasal Degeneration 15
1.2.4. Parkinson’s Disease 15
1.2.5. Huntington’s Disease 18
1.3 The AS/AGU Rat 19
1.3.1. The AS/AGU Mutation 21
1.4. Aims of the Study 21
2. M aterials and M ethods 22
2.1. Locomotor Assessment 22
2.1.1. Inclined Ramp Test 23
2.1.2. Mid-air Righting 24
2.1.3. Gait Analysis 25
2.1.4. Infra-red Movement Analysis 28
111
2.2. L-DOPA Treatment 30
2.2.1 Locomotor Assessment 30
2.2.2. Measurement of Extracellular Levels of Dopamine, 30
DOPAC and HVA in the Striatum
2.3. Statistical Analysis 38
3 . R esults 39
3.1. Locomotor Assessment 39
3.1.1. Inclined Ramp Test 39
3.1.2. Mid-air Righting 42
3.1.3. Gait Analysis 43
3.1.4. Infra-red Movement Analysis 47
3.2. L-DOPA Treatment 49
3.2.1. Inclined Ramp Test 49
3.2.2. Mid-air Righting 52
3.2.3. Measurement of Extracellular Levels of Dopamine, 53
DOPAC and HVA in the Striatum
4. D iscussion 58
4.1. Locomotor Assessment Techniques 58
4.2. Locomotor Characterisation of the AS/AGU Rat 61
4.3. The Effects of Age on Locomotor Behaviour 62
in the AS/AGU Rat
4.3.1. Inclined Ramp Test 62
4.3.2. Mid-Air Righting 64
4.3.3. Gait Analysis 65
4.3.4. Infrared Movement Analysis 6 6
4.4 L-DOPA Replacement 67
4.4.1. Pharmacokinetics 68
4.5 The AS/AGU Rat as a Model for a Movement Disorder 70
5. C onclusions 72
6. R eferences 74
7. A ppendices 83
IV
LIST OF FIGURES
Figure 1 : Basal Ganglia Circuitry
Figure 2: Normal and Abnormal Basal Ganglia Circuitry
Figure 3: Inclined Ramp Test
Figure 4: Mid-Air Righting
Figure 5: Footfall Chamber
Figure 6 : Foot Pad Arrangements in Hind Foot
Figure 7: Digitized Footfall Patterns
Figure 8 : Infrared Movement Monitoring System
Figure 9: Rat Striatal Brain Section
Figure 10: Microdialysis Probe
Figure 11 : HPLC Chromatograms
Figure 12: Effects of Age on Inclined Ramp test
Figure 13 : Effects of Age on Mid-Air righting
Figure 14: Gait Analysis Scatter Diagram
Figure 15: Gait Analysis Footfall Histogram
Figure 16: Infrared Activity (short sessions)
Figure 17: Infrared Activity (long sessions)
Figure 18: Effects o f L-DOPA on Inclined Ramp Test in AS Rats
Figure 19: Effects of L-DOPA on Inclined Ramp Test in AS/AGU Rats
Figure 20: Effects of L-DOPA on Mid-Air Righting in AS Rats
Figure 21 : Effects of L-DOPA on Mid-Air Righting in AS/AGU Rats
Figure 22: Microdialyis Levels of Dopamine and it’s Metabolites with L-DOPA
Figure 23: Time Course Charts Following L-DOPA Bolus Injection
PUBLICATIONS
From This Study
Payne, A.P., Campbell, J.M., Russell, D. et al. (2000) The AS/AGU rat: a spontaneous 
model of disruption and degeneration in the nigrostriatal dopaminergic system . J. Anal 
196: 629-633.
Campbell, J.M., Gilmore, D.G., Russell, D. et al. (2000) Pharmacological analysis of 
extracellular dopamine and metabolites in the striatum of concious AS/AGU rats, mutants 
with locomotor disorder. Neurosci,, 100(1): 45-52.
Campbell, J.M., Favor, G., Russell, D. et al. (1999) A microdialysis study of evoked 
dopamine release and re-uptake blockade in the AS/AGU rat. Congress o f  the Turkish 
physiological society abstracts. P87.
Russell, D., Campbell, J.M., Favor, G. et al (1998) Locomotion in the AS/AGU mutant 
rat: progressive deficits and the effects of L-DOPA replacement. Society for Neuroscience 
Abstracts 24: 1718.
General Publications
Al-Fayez, M.A.S., Russell, D., Campbell, J.M. et al. (2001) Deficiencies in the raphe- 
striatal serotonergic system of the AS/AGU rat XIV  International Congress on 
Parkinson's Disease abstracts.
Payne, A.P., Sutcliffe, R.G., Campbell, J.M. et al. (1998) Disordered locomotion in the 
AS/AGU mutant rat and the effects of L-Dopa or fetal midbrain grafts. Movement 
Disorders 13: 832-834.
Campbell, J.M., Gilmore, D.P., Russell, D. et al. (1998) Microdialysis studies of dopamine 
and i f  s metabolites in the corpus striatum of conscious AS/AGU mutant rats. Neurosci., 
85: 323-325.
Campbell, J.M,, Payne, A.P., Gilmore, D.P. et al. (1997) Age changes in dopamine levels 
in the corpus striatum of albino Swiss (AS) and AS/AGU mutant rats. Neurosci Lett 239: 
54-56.
Campbell, J.M., Payne, A.P., Gilmore, D.P. et al.(1996) Neostriatal dopamine depletion 
and locomotor abnormalities due to the albino Swiss rat agu mutation. Neurosci Lett 213: 
173-176.
VI
LIST OF ABBREVIATIONS
6 -OH-DA
ACSF
AMPA
AS
AS/AGU
CM/PF
CNS
COMT
DHBA
DOPAC
EDTA
EPN
GABA
GP
Gpe
Gpi
HBN
HD
HPLC-ECD
HVA
L-AAAD
L-DOPA
MAO
MPTP
MSA
NMDA
PD
PKCy
PET
6 -Hydroxydopamine 
Artificial Cerebrospinal Fluid
Alpha-amino-3 -hydroxy-5 -methyl-4-isoxazolepropionate 
Albino Swiss
Albino Swiss/Anatomy Glasgow University
Centromedian-Parafasicular
Central Nervous System
Cateehol-o-Methyl Transferase
Dihydroxybenzylamine
3,4-Dihydroxyphenylacetic Aeid
Diaminoethanetetra-acetic Acid
Entopenduncular Nucleus
Gamma-Aminobutyric Acid
Globus Pallidus
External Globus Pallidus
Internal Globus Pallidus
Lateral Habenular Nucleus
Huntington’s Disease
High Performance Liquid Chromatography with Electrochemical
Detection
Homovanillic Acid
L-Aromatic-amino Acid Decarboxylase 
L-3,4-Dihydroxyphenylalanine 
Monoamine Oxidse
1 -Methyl-4-Phenyl-1,2,3,6 -T etrahydropyridine 
Multiple System Atrophy 
N -methyl-D-aspartate 
Parkinson’s Disease 
Protein Kinase C gamma 
Positron Emission Tomography
Vll
PPN Pendunculopontine Tegmental Nucleus
PSP Progressive Supranuclear Palsy
RF Response Factor
SC Superior Colliculus
SN Substantia Nigra
SNpc Substantia Nigra Pars Compacta
SNpr Substantia Nigra Pars Reticulata
STN Subthalamic Nucleus
Thai Thalamus
VM-VL Ventromedial A/ entrolateral Complex
VTA Ventral Tegmental Area
VI11
SUMMARY
The AS/AGU mutant rat was derived from Albino Swiss (AS) parent 
stock and is characterised by an ungainly staggering gait, hindlimb rigidity, 
whole body tremor and difficulty in initiating movement. It is highly deficient 
in extracellular dopamine in the dorsal caudate-putamen. It is important to 
know which aspects of locomotor performance show progressive deficits and 
which ones are responsive to L-DOPA replacement. Initially, locomotor tests 
were video-recorded and used to assess an age series of both AS/AGU 
(mutant) and AS (parent strain) rats between 20 days and 1 year. Progressive 
deficits with age (with initial success c. 80-90% declining to nil at one year) 
were found in the performance of simple tasks such as mid-air righting (being 
dropped upside down from 50cm and successfully turning) and walking down 
a series of inclined ramps of increasing width and not falling off. In infra-red 
monitoring, mutant rats actually showed more movement than controls a) in 
an acute test of 12 minutes and b) in extended tests of 22 hours. Secondly, 
images taken from a footfall chamber were studied using a Kontron image 
analysis system to determine paw contact patterns. In AS rats, whilst contact 
progresses forwards it is centred around the midline of the foot throughout. 
Conversely, mutant rats exhibited frequent footfalls in which contact was 
eccentric (either medial or lateral). There appeared to be most contact on the 
medial side of the foot than on the lateral side, confirming the staggering gait 
nature of the AS/AGU rat. This is indicative of the animals inability to balance 
as well as its failure to sustain purposeful movement. The several elements of 
the movement disorder are brought back into the wild-type range by treatment
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with L-DOPA administration (25 mg/kg/day ip + benserazide 2.5mg/kg/day 
ip) for 4 weeks. This drug is the standard treatment for human Parkinson’s 
Disease. L-DOPA ameliorated mid-air righting, and performance on certain 
inclined ramps in AS/AGU rats. Most striking was the improvement in 
locomotor performance on a 5 cm ramp after week 3 of treament. The width of 
this ramp corresponded to the AS/AGU rat’s natural gait width. The 
improvement of AS/AGU rats in both of these simple locomotor tasks, 
continued to improve over the course of the study.
These results indicate that the progressive nature of the AS/AGU movement 
disorder and its amelioration after L-DOPA treament, would suggest that this 
rat could prove to be invaluable to the study of basal ganglia related disorders. 
It is therefore suggested that this naturally occurring mutant model could have 
many advantages over existing animal models, such as those with 6 -OHDA 
and MPTP lesions.
INTRODUCTION
INTRODUCTION
1.1 The Basal Ganglia
As early as 1664, a number of subcortical structures were identified and described 
by the British anatomist Thomas Willis. What is now known as the basal ganglia were then 
referred to as the corpus striatum, a structure thought to both receive all sensory modalities 
and initiate all motor acts. This idea seemed to be reinforced by its central position and 
visible ascending and descending fibre systems.
As the histological organisation of the cortex became clearer, it became obvious 
that many of the functions originally assigned to the corpus striatum were in fact properties 
of neighbouring eorticospinal paths (Wilson, 1914). At the beginning of the twentieth 
century, the corpus striatum was studied in some detail and gained particular importance 
when it was discovered that lesions of its component parts often resulted in disorders of 
motor functions in humans.
The term "extrapyramidal motor system” loosely grouped the striatum with an array 
of brain stem nuclei and reflected the growing assumption that this grouping constituted a 
complete and independent motor unit (Carpenter, 1981). The term basal ganglia has been 
generally used to refer to these anatomical telencephalic subcortical nuclei at the base of 
the forebrain.
1.1.1 Components of the Basal Ganglia
The term basal ganglia refers to the large nuclear masses i.e., the caudate, putamen 
and globus pallidus (GP), which are found in the basal part of the telencephalon and are 
best known for their motor functions. The substantia nigra (SN) and subthalamic nucleus 
(STN), both closely related to the preceding structures, are also usually considered part of
the basal ganglia. These structures are linked together by a complex series of intrinsic 
loops, most of which are reciprocal, and to other brain structures (cortex and thalamus) by 
a parallel circuit. Other regions that are important for basal ganglia function are cortical 
motor, somatosensory and premotor areas; ventral anterior (VA), ventrolateral (VL), and 
centromedian-parafascicular (CM-PF) nuclei of the thalamus; monoamine containing cell 
groups such as ventral tegmental area, retrorubral field, dorsal raphe nucleus and the 
tegmental pedunculopontine nucleus. Together these nuclei enable not only controlled 
motor execution but also more complex aspects of behaviour such as motor planning and 
sequencing, motor learning, and cognitive and motivational drives.
1.1.2. Striatum
The term striatum refers to the functional unit of caudate nucleus and putamen, 
together called the dorsal striatum or neostriatum. In man the caudate nucleus is a large C- 
shaped structure located chiefly medial to the internal capsule and related throughout its 
length to the lateral ventricle. It has a large rostral component (head) that bulges into the 
lateral wall of the anterior horn of the lateral ventricle. The head tapers to form the body 
which in turn fiirther attenuates to form the tail terminating at the amygdaloid body. The 
putamen is separated, though incompletely, from the caudate nucleus by the internal 
capsule. The ventral striatum is the region at the base of the caudate-putamen complex that 
lies mainly anterior to the anterior commisure. The ventral continuations of the caudate 
nucleus and putamen, the nucleus accumbens septi and parts of olfactory tubercle are all 
contained within the ventral striatum.
Striatal neurons are of two different types, projection neurons and intemeurons. 
About 90 percent are medium sized (12-20pm diameter) with spiny dendrites (Wilson, & 
Groves, 1980), and have a receptive/outflow (projection) function. They use gamma-
aminobutyric acid (GABA) as their main neurotransmitter (Oertel & Mugnaini, 1984; 
Ribak et ah, 1979), but also co-express neuroactive peptides, such as substance P, 
enkephalin, dynorphin and neurotensin (Fallon & Leslie, 1986; Hokfelt et al., 1977). The 
remaining striatal neurons are of large elongated (50x15 pm) and medium (14-15 pm) 
sizes, lack dendritic spines, and function as intrinsic intemeurons, using the excitatory 
transmitter acetylcholine (Ach).
1.1.3. Globus Pallidus
The globus pallidus (GP) or palaeostriatum, represents the efferent side of the basal 
ganglia. It is situated medial to the putamen and is separated from it by the external 
medullary lamina. The GP is divided into external (GPe) and internal (GPi) segments by 
the medial medullary lamina, and is traversed by numerous myelinated fibres giving it a 
characteristically pale appearance in stained sections. Both segments contain a relatively 
small number of large neurons which typically have long dendrites whose branching tends 
to be discoidal in nature. These dendritic formations lie parallel to the lateral segmental 
boundaries.
1.1.4. Substantia Nigra.
The substantia nigra (black substance) is an elongated nucleus located medial to the 
basis pendunculi throughout the rostrocaudal extent of the midbrain. Although a 
component of the midbrain it is considered part of the basal ganglia due to its functional 
significance. The SN is divided into two distinct parts: the ventrally situated pars reticulata 
(SNpr), and the more dorsal pars compacta (SNpc), which have different connections and 
distinct neurotransmitters.
1.1.5. Subthalamic nucleus
The subthalamic nucleus is a biconvex structure located within the caudal 
diencephalon ventral to the thalamus and just medial to the internal capsule.
1.1.6. Compartmental Organisation of the Striatum.
Regular Nissl staining of the striatum shows a largely homogeneous mass. 
Discontinuous areas were observed, however, when techniques such as retrograde tracing 
were combined with histochemistry, immunohistochemistry and histopharmacology. Two 
levels of eompartmental organisation have been described in the striatum: patch-matrix 
compartments, and the organisation of separate striatopallidal and striatonigral systems. 
Striatal patch-matrix systems are demonstrated and determined by specific neurochemical 
markers and also by underlying neuronal connections. The patch compartment is defined 
by p-opiate binding (Herkenham & Pert, 1981), and by low expression of 
acetylcholinesterase (Butcher & Hodge, 1976). The term striosome ("striatal body") was 
first used by Graybiel and Ragsdale (1978), to describe these areas of low cholinesterase 
activity. Five-nucleotidase (Schoen & Graybiel, 1992) was also found to be an excellent 
marker for striosomes in the rat.
The matrix compartment can be defined by staining for the calcium binding protein 
calbindin, and by the immunoreactivity of somatostatin positive fibres (Gerfen et ah, 1985). 
Patch-matrix organisation is predominantly found in the caudate- putamen, extending into 
the dorsolateral and ventromedial areas.
In the rat, it was observed that compartmental organisation of cortico-striatal 
afferents was related to their laminar origin rather than in their cortical areas of origin 
(Gerfen, 1989), with different cortical laminae innervating patch and matrix compartments. 
Thus, eorticostriatal neurons in infragranular layers project principally to patches, with the
matrix being the main recipient of axons from supragranular layers. A similar pattern exists 
in primates but is complicated by the fact that allocortical areas have a higher concentration 
of eorticostriatal neurons arising from infragranular layers, whereas in neocortical areas, 
supragranular eorticostriatal neurons are more numerous (Arikuni & Kubota, 1986). These 
eorticostriatal projections terminate principally on the dendrites of medium spiny 
projection neurons where they have an excitatory effect due to glutamate. These findings 
are consistent with studies that show the developmental relationship between medium 
spiny neurons of the patches and matrix, and neurons of deep and superficial cortical 
laminae respectively (Fishell & van der Kooy, 1987).
If striatal medium spiny neurons can be divided into two populations (patch and 
matrix) that have a relationship with the laminar (Gerfen, 1989) and regional (Donoghue & 
Herkenham, 1986) organisation of the cortex, they can also be characterised by their 
respective projections to globus pallidus, entopenduncular nucleus (EPN) and substantia 
nigra, with striatopallidal neurons arborizing within the GP, and striatonigral neurons 
extending to the EPN and SN (Parent et al., 1984). Gerfen (1992) hypothesised that 
striatopallidal projections to mainly cholinergic and substance P expressing areas of the 
ventral pallidum originate largely in the patch striatal area, whereas matrix neurons tend to 
project to the predominantly GABAergic enkephalin-containing neurons.
Tracing techniques in rats have shown that although both types of neurons project 
to the substantia nigra, patch neurons project to the dopaminergic cell groups in the SNpc, 
and cell islands in the SNpr, whereas matrix neurons project to areas in the SNpr 
containing GABAergic neurons (Gerfen, 1984; 1985).
1.1.7. Parallel organisation of cortico-basal ganglia loops.
Early data on the function of the basal ganglia suggested its role in the assimilation 
of information coming in from all areas of the cerebral cortex, funnelling through the 
ventrolateral thalamus specifically to the motor cortex to complete a circuit that would 
facilitate, amongst other things, the initiation and control of movement (Kemp & Powel, 
1971; Alexander et al., 1986). A revised view was formed when subsequent studies showed 
the segregation of information from the sensorimotor and associative cortices through the 
basal ganglia-thalamocortical pathways (DeLong & Georgeopoulus, 1981). It was 
suggested at that time that there might be two separate eircuits through the basal ganglia 
i.e. the "motor" loop, passing mainly through the putamen, receiving inputs from the 
sensorimotor cortex transmitting ultimately to premotor areas, and the "association" or 
"complex" loop which took information from the assoeiation areas, passed through the 
caudate nucleus, ultimately returning to areas of the prefrontal cortex (DeLong & 
Georgeopoulus, 1981; DeLong et al., 1983).
There is good neuroanatomical and neurophysiological evidence that primate 
supplementary motor area I and the frontal eye field give rise to pathways in which the 
basal ganglia-thalamocortical outputs remain segregated and terminate in the cortical areas 
from which they originated, thus forming largely closed "motor"and "oculomotor" circuits 
(Alexander & Crutcher, 1990; Hoover & Strick, 1993).
The organisation of eorticostriatal systems has been described by Alexander et. 
al.(1986). Segregated parallel circuits connect limbic, prefrontal, oculomotor and motor 
cortical areas through specific subregions of the basal ganglia, which in turn project back to 
the same cortical areas via ventral tier thalamic nuclei. There seems, therefore, to be a 
progressive "funnelling" of multiple corticostriate inputs at striatal, pallidal/nigral and
thalamic levels. It also seems that each basal ganglia-thalamocortical circuit uses multiple 
inputs only from cortical areas that are functionally related and mostly interconnected.
The five proposed basal ganglia-thalamocortical circuits (motor, oculomotor, 
dorsolateral prefrontal, lateral orbitoffontal and anterior cingulate) each involve specific 
regions of the cerebral cortex, striatum, pallidum, substantia nigra and thalamus. The best 
understood is the motor cireuit.
1.1.8. The Motor Circuit
The motor circuit begins with major somatotopically organised excitatory 
projections, which use glutamate as a neurotransmitter from the motor (Kunzle, 1975), and 
somatosensory (Kunzle, 1977) cortices. In primates, both motor and somatosensory cortical 
"leg" areas project to a dorsolateral area, the "face" areas to a ventromedial area and the 
"arm" areas to an region in between (Kunzle, 1975; 1977). In addition to motor and 
somatosensory projections, the putamen also receives inputs from area 5, lateral area 6 
including the arcuate premotor area, and from the supplementary motor area (Alexander & 
Crutcher, 1990). Although outputs from each area venture slightly into neighbouring areas 
of the caudate nucleus, the putamen controls all of the terminal arborizations.
The putamen sends topographically organised efferents to the ventrolateral two 
thirds of both the internal and external segments of the globus pallidus (Devito et al., 1980; 
Parent et al, 1990), and to caudolateral portions of the substantia nigra (Parent et al, 1990). 
The portion of the GPi segment that receives putamen efferents projects in turn to the oral 
part of the ventrolateral nucleus of the thalamus (Vlo) (Devito & Anderson, 1982). Schell 
& Strick (1984) showed that the Vlo projects to the supplementary motor area. It is thus 
demonstrated that somatotopically organised projections from the supplementary motor 
area, the arcuate premotor area, motor cortex and somatosensory cortex exert their
influence through the motor circuit projecting ultimately back to a single cortical region, 
the supplementary motor area. Each basal ganglia-thalamocortical circuit contains separate 
parallel "direct" and "indirect" pathways to the output nuclei (GPi, SNr, and ventral 
pallidum) (Figure 1).
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Figurel. An updated version o f  the basal ganglia cireuitry originally represented by Alexander and Crutcher 
(1986), showing the connectivity o f  the direct and indirect pathways o f the basal ganglia. Inhibitory projections are 
shown as filled arrows, exitatory projections as open arrows. GPe = external segment o f the globus pallidus; SNc = 
substantia nigra pars compacta; SNr =  substantia nigra pars reticulata; STN = subthalamic nucleus; Thai = thalamus; PPN 
=  pedunculopontine tegmental nucleus; HBN = lateral habenular nucleus; SC = superior colliculus; and RF =  reticular 
formation.
The "direct" pathway arises from inhibitory striatal efferents, projecting from spiny 
neurons directly to the output stations that contain both GABA and the neuropeptides 
Substance P (Albin et al., 1989), and dynorphin (Vincent et al., 1982). These neurons 
preferentially express the Di subtype of dopamine receptor. Activation of this pathway 
disinhibits the thalamic stage by double inhibition, as the subsequent thalamic afferents are 
also inhibitory projections (Chevalier et al., 1985). In addition to the cerebral cortex, the 
intralaminar thalamic nuclei are a major source of glutamatergic inputs to the striatum.
In the "indirect" pathway, striatal efferents project from spiny neurons and contain 
GABA and the neuropeptide enkephalin (Alexander & Crutcher, 1990). These neurons
preferentially express the D2 subtype of dopamine receptor. These projections exert an 
inhibitory influence on the GPe which in turn projects to the subthalamic nucleus via a 
purely GABAergic pathway, and finally to the GPi/SNr via an excitatory glutaminergic 
projection from the subthalamic nucleus. The GAB A/enkephalin inhibiting influence on 
the GPe from the striatum tends to suppress the activity of striatal neurons which, along 
with the similar inhibitory influence of GPe neurons on the subthalamic nucleus, has the 
net effect of disinhibition on the subthalamic nucleus. This increases the excitatory drive 
on the output nuclei (GPi, SNpr and EPN), subsequently increasing inhibition of their 
efferent targets within the thalamus. One of the most important new findings is the 
demonstration of multiple indirect pathways of information flow through the basal ganglia. 
In addition to the classic indirect route via GPe and STN, the GPe has been shovm to 
project also to the output nuclei (SNpc/Gpi) as well as to the reticular nucleus of the 
thalamus. These projections are GABA-ergic in nature. The cortico-subthalamic projection 
is an additional route by which cortical information flows in order to reach the basal 
ganglia output structures (Smith et al., 1998).
Thus the "direct" and "indirect" pathways have opposite effects on the output nuclei 
(inhibition and activation respectively). This in turn has differing effects on thalamic 
targets, with the "direct" pathway disinhibiting, and the "indirect" pathway inhibiting the 
target nuclei.
The thalamic targets include the ventromedial/ventrolateral complex (VM-VL), the 
centromedian-parafasicular complex, and the mediodorsal nucleus and adjacent 
intralaminar nuclei. Other targets of the entopenduncular nucleus and SNr are the superior 
colliculus and the pendunculopontine tegmental nucleus (Parent, 1990).
The concept of two opposing pathways has been a major factor in the advancement 
of research on the anatomical and functional aspects of the basal ganglia. It has also led to
the development of new therapies and surgical strategies in the treatment of basal ganglia 
disorders such as Parkinson's disease and Huntington's chorea.
1.1.9. The Dopaminergic Svstem
Neurons in the SNpc are typically densely packed and are 11-20pm in size. They 
have dendrites which spread ventrolaterally into the SNpr. Dopamine released from these 
dendrites interacts with dopamine autoreceptors, and with dopamine receptors on adjacent 
dopamine neurons (Cheramy et al., 1981). A second type of neuron is medium sized 
radiating medio-laterally, but without apical dendrites that run into the SNpr. This 
separation of dendritic projections forms the basis for the functional segregation of input 
and output areas in the SNpc (Gerfen, 1992). A third type of neuron, a non-dopaminergic 
intemeuron, makes up about 10% of the SNpc total.
80% of the neurons in the VTA are dopaminergic. The rat VTA has more in 
common with human than with non-human primates which gives added validity to the use 
of the rat brain as a model for human study (Halliday & Tork, 1986).
Projections from the SNpc and VTA to the cortex, striatum and to a lesser degree pallidum 
arise topographically and are largely ipsilateral. These projections have a significant 
influence on post synaptic neurons and play an important part in the role of dopamine in 
facilitating loops and outputs in the extrapyramidal motor system.
It is not only the substantia nigra, however, that provides dopaminergic inputs to the 
striatum. Other midbrain dopaminergic cell groups which do so include: the retrorubral 
region (Cell group A8 which is contiguous with the caudal portion of the SNpc); and the 
medially situated ventral tegmental area (A 10) which is the main source of dopamine for 
the ventral striatum, prefrontal cortex and limbic targets although these regions also receive 
some connections from the medial SNpc (Fallon & Loughlin, 1995).
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There are four main inputs to the SNpc, (which is also referred to as group A9 in 
the mesencephalon): striatal input from striosomes and ventral striatum; limbic inputs 
from amygdala and lateral preoptic area of the hypothalamus; cortical inputs from 
prefrontal cortex including premotor cortex; and some fibres from pallidum and 
subthalamic nucleus. Thus, a number of nuclei, many related to the limbic system, are able 
to have an influence on striatal activity via the dopaminergic connections from the SNpc 
(Fallon & Loughlin, 1995).
Dopaminergic neurons are strongly influenced by striatopallidal inputs. The 
presence in differing degrees of both dopaminergic and GABA-ergic neurons in the SNpc 
and VTA allow similar striatal projections to influence both systems simultaneously. For 
example, axons arising from the striatal matrix may terminate on both SNpr GABA-ergic 
neurons and SNpc dendrites that extend from the SNpc to the SNpr.
Dopaminergic inputs to the striatum follow an ordered pattern. Although some 
nigral dopaminergic cells project to both striatal compartments, the ventral part of the 
SNpc and the SNpr (in rats) exclusively innervate striosomes whilst other dopaminergic 
cells (cell groups A8 and AlO) project only to matrix (Fallon & Loughlin, 1995).
Neurons projecting to these different areas could be under different presynaptic 
control. An indication of differences between these neurons is the fact that dopaminergic 
cells which innervate striosomes develop to maturity more quickly (Graybiel, 1990), while 
those which innervate matrix areas exhibit a faster dopamine turnover, contain the calcium 
binding protein calmodulin, and are more sensitive to MPTP toxicity.
Dopamine projections from SNpc/VTA extend to various other structures including 
the caudate-putamen, nucleus accumbens, olfactory tubercule, amygdala, and also to 
prefrontal, cingulate, perirhinal and entorhinal cortices. Non-dopaminergic projections
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include thalamus, superior and inferior colliculi, mesopontine tegmental/PPN and visual 
cortex (Fallon & Loughlin, 1995).
1.1.10. Dopamine receptors in the striatum
The dopamine receptor can be divided into five subtypes, Di to D5.This section will 
focus mainly on Di and D2 subtypes. Several studies have shown that these receptors are 
localized postsynaptically on different striatal neuronal systems. Di is expressed on striato­
nigral (direct) neurons, D2 on striato-pallido-subthalamo-nigral neurons (Gerfen, 1990). 
Other studies have also concluded that about 20-40% of D2 receptors are localized on 
cortico-striatal terminals (Schwarcz et al., 1978). This, however, has been debated (Filloux 
et ah, 1988).
Dopaminergic inputs to the striatum have differing effects on the 'direct' and 
'indirect' pathways. Dopamine has an excitatory influence on the 'direct' pathway via Di 
receptors and the neuropeptides substance P and dynorphin. In the 'indirect' pathway, 
dopamine has an inhibitory effect via D2 receptors, that is influenced by enkephalin. When 
dopamine is substantially depleted, for example in Parkinson's disease or in rats with 6 - 
OHDA lesions, the resulting effect on the 'direct' pathway is to reduce the inhibitory 
influence of striatal GABA-ergic neurons on SNpr/GPi, thus increasing inhibition of the 
thalamus and reducing locomotor activity. In the 'indirect' pathway, a reduction in 
dopamine has the effect of increasing enkephalin and there is an increased firing of striatal 
GABA-ergic neurons due to reduced inhibition via dopamine, which results in down 
regulation of the GPe and subsequent over-activity of the STN. This has the effect of over 
inhibiting the thalamus.
In a review article. Levy and colleagues (1997) consider studies that suggest that the 
GPe is not hypoactive in Parkinson's disease or in MPTP monkeys, and that the activity of
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GPe neurons is not dependent only upon striatal influence, but perhaps also upon excitatory 
projections such as those from the STN via a sub-loop (glutamate), cortex (glutamate), 
parafasicular nucleus (glutamate), and SNpc (dopamine).
Cortico-striatal glutamatergic neurons innervate either striosomes or matrix 
depending on the layer of origin. They project onto medium spiny GABA-ergic neurons 
that activate both direct and indirect pathways. In vitro studies have shown glutamate also 
stimulates tonic and phasic dopamine release presynaptically via AMPA (alpha-amino-3- 
hydroxy-5-methyl-4-isoxazolepropionate) and NMDA (N-methyl-D-aspartate) receptors, 
some of which are located on dopamine nerve terminals (Krebs et al., 1991; Gauchy et al., 
1991). Dopamine itself inhibits its own release by acting on DA autoreceptors (D2 and D3) 
on dopamine nerve terminals. Acetylcholine, located in striatal intemeurons, can also 
facilitate or reduce the release of dopamine (Gauchy et a l, 1991).
1.1.11. The 6 -Hvdroxvdopamine (6 QHDA) rat model
Experiments relating to the role of the substantia nigra and the striatum in motor 
control have given an insight into the site of dopamine action in the nigrostriatal circuit. 
Ungerstedt (1968) developed the 60HDA rat model for the dopaminergic loss in 
Parkinson's disease. This destruction of the nigrostriatal pathway, and unilateral loss of 
dopamine release, was achieved by a unilateral injection of the toxin into the ascending 
forebrain bundle. Dopaminergic cell loss in the SNpc results in reduced tonic dopamine 
release in the striatum due to a reduction in the number of terminals. Compensatory 
mechanisms such as the sprouting of remaining terminals, increased production and release 
from these terminals, and an increase in the of postsynaptic dopamine receptor numbers 
were found to be a feature of these models.
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1.2. Movement Disorders
Dysfunction of the basal ganglia is the root cause of many movement disorders. 
These diseases can be classified into two categories; hypokinetic and hyperkinetic. 
Hyperkinetic diseases sueh as Huntington's disease are generally associated with decreased 
output from the basal ganglia, and are characterised by an excess of movement that tends to 
be uncontrolled and relatively rapid.
Hypokinetic diseases, such as Parkinson's disease, are associated with increased 
basal ganglia output which typically results in symptoms sueh as akinesia, bradykinesia and 
rigidity (Albin et ah, 1989). Pharmacologically, they tend to show the inverse of 
hyperkinetic diseases in that they are exacerbated by D2 antagonists and cholinergic 
agonists, and are improved with dopamine agonists and anti-cholinergic treatment (Lang & 
Lozano, 1998).
1.2.1. Multiple Svstem Atronhv
The term multiple system atrophy (MSA) refers to a group of sporadic hypokinetic 
disorders that tend to occur in middle age, presenting with extrapyramidal, cerebellar or 
autonomic symptoms (Wenning et ah, 1997). Symptoms include ataxia, rigidity and general 
autonomic failure. Degeneration occurs in a variety of subcortical systems clinically 
presenting as striato-nigral degeneration, in which Parkinsonism predominates; 
olivopontocerebellar atrophy, which affects balance, coordination and speech, and Shy- 
Drager syndrome in which such autonomic functions as blood pressure and urinary control 
are also affected. Levodopa is an effective treatment in striato-nigral degeneration.
Pathological studies have shown that up to 10% of patients thought to have 
Parkinson's disease actually have MSA.
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1.2.2. Progressive Supranuclear Palsy
Progressive Supranuclear Palsy (PSP), also known as Steele-Richardson-Olszewski 
syndrome, is a sporadic, late-onset hypokinetic disease that is rarely familial. It is clinically 
characterised by rigidity, akinesia, postural instability, vertical gaze palsy and frontal lobe 
dementia, and is L-DOPA resistant. One to eight percent of patients with Parkinsonism 
suffer from this syndrome (Collins et al., 1995). Nigrostriatal dysfunction is the main cause 
of PSP with an 80-90% decrease in dopamine, tyrosine hydroxylase and D% receptors in the 
striatum. Damage to the SNpr, STN and pallidum causes severe disruption of the pathways 
to the motor thalamus.
1.2.3. Corticobasal Degeneration
This rare, late onset disorder may clinically resemble Idiopathic Parkinson's disease 
and PSP (Bergen et al., 1998). It is characterised hy an asymmetrical akinetic-rigid 
syndrome associated with cognitive (apraxia and aphasia) and extrapyramidal motor 
dysfunction (rigidity and dystonia). Moderate dementia is occasionally observed late in the 
course of the disease.
Neui'opathological examination reveals lobar frontal or parietal atrophy, severe 
neuronal loss and gliosis in the cortex with the presence of swollen, achromatic, tau- 
positive staining Pick cells. The basal ganglia and substantia nigra show severe 
degeneration. The disease is poorly L-DOPA responsive.
1.2.4. Parkinson's Disease
Described over 180 years ago by James Parkinson (1817), Paikinson's Disease 
(PD), the classic hypokinetic disorder, is characterised by its main symptoms, namely,
15
resting tremor, rigidity, bradykinesia, and akinesia. There is also disruption of normal gait 
patterns and of posture. Dementia is an important part of PD in elderly patients with the 
frequency being 6.6% up compared with normal ageing (Mayeux et al., 1990). Pathological 
examination in PD remains the only means of diagnosis and there is still no biological 
marker. Pathology normally reveals significant cell losses in dopaminergic neuromelanin 
containing cells in the SNpc, serotonergic cells in the raphe nucleus, noradrenergic cells in 
the locus ceruleus, the cholinergic nucleus basalis of Meynert, hypothalamus, small cortical 
neurons particularly in cingulate gyrus and entorhinal cortex, olfactory bulb, sympathetic 
ganglia, and parasympathetic neuions in the gut (Lang & Lozano, 1998). The presence of 
Lewy bodies is also a pathological feature.
SNpc loss is greatest in the ventrolateral tier (60-70% at onset), followed by the 
medial ventral tier and dorsal tier. This pattern is relatively specific to PD (Feamley & 
Lees, 1991). These dopaminergic deficits result in regional loss of striatal dopamine, 
mainly in the dorsal and intermediate subdivisions of the putamen (Kisch et al., 1988). 
This is believed to account for akinesia and rigidity.
Among the factors thought to cause neurodegeneration in PD (Olanow & Tatton, 
1999) are:
i.) Oxidative stress, where damaging levels of hydrogen peroxide and other reactive 
oxygen species are increased as a result o f a) increased dopamine turnover, b) a deficiency 
in glutathione, and c) a build up of reactive iron which can lead to hydroxyl radical 
formation.
ii) Mitochondrial dysfunction, in which a selective decrease in complex 1 activity of the 
mitochondrial respiratory chain affects the SNpc.
iii) The toxic effects of increased glutamate formation.
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The resurgence of surgical procedures as treatment for PD has come with the 
increased understanding of the pathophysiology of the disease. Medial pallidotomy has 
been shown to be effective in reducing or even abolishing L-DOPA induced dyskinesias 
(Dogali et al., 1995). High frequency electrical pallidal stimulation is reported to give 
similar results (Arcusa et al., 1996). Given that striatal dopamine depletion in PD is 
associated with reduced inhibition of the GPi (Figure 2), the improvements due to pallidal 
surgery seem to have the effect of removing this excessive inhibition, reducing it's 
inhibitory effect on the thalamus, and thereby facilitating movement. Other surgical 
approaches involve the stimulation of STN, which reduces it’s excitatory input to, and 
stimulation of the thalamus. The latter effectively abolishes tremor (Benabid et al., 1991).
Normal
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Figure 2. Basal ganglia thalamocortical circuitry A) under normal conditions. B) with Parkinson’s disease C) with 
Huntington’s disease. Inhibitory projections are shown as filled arrows, exitatory projections as open arrows. Changes in 
arrow thickness reflect difierential changes between disease states.
GPi = internal segment o f the globus pallidus; GPe = external segment o f the globus pallidus; SNc = substantia nigra pars 
compacta; SNr = substantia nigra pars reticulata; STN = subthalamic nucleus; VL=ventrolateral thalamus; PPN = 
pendunculopontine tegmental nucleus; CM/PF = centromedian/farafasicular nucleus o f  the thalamus. From W ichm ann  
and D eL ong (1998).
A range of drugs has been used to treat PD with various levels of success. The 
dopamine precursor L-DOPA has for many years been the most effective. Used along with 
the decarboxylase inhibitor carbidopa, it is converted to dopamine thus improving striatal
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deficits. The prolonged use of L-DOPA can, however, result in hyperkinetic type abnormal 
involuntary movements (Marconi et al., 1994).
Other drug types include acetylcholine blockers ( trihexy phenidyl, benztropine), 
dopamine metabolism enzyme (MAO/COMT) blockers (selegiline, tolcapone), and 
dopamine agonists which mimic the action of dopamine on dopamine receptors 
(bromociyptine, apomorphine).
1.2.5. Huntington's Disease
A hyperkinetic disorder, Huntington’s Disease (HD) was first described as a specific 
disease in 1872 by the American Physician George Huntington, who believed that the 
distinguishing features of the disorder, namely the late onset and its hereditary nature, made 
it quite distinct ifom the chorea described prior to its discovery. The mutation which is 
responsible for HD is an expanded polyglutamine repeat, (CAG), within exon 1 of the gene 
that codes for the protein Huntingtin (Reddy et al., 1999; Hedreen & Folstein, 1995).
HD is the classic hyperkinetic disorder eharacterised by progressive chorea, rigidity, 
dementia, dystonia, cognitive deficits and psychological disturbance. It is an autosomal 
dominant hereditary neurodegenerative disease. Pathologically, there is an apparent non- 
random degeneration of medium sized striatal projection neurons early in the course of the 
disease. Striatal GABA-ergic output neurons projecting to the GPe appear to be affected 
initially. The dying off of these neurons leads to reduced inhibition of neurons in the GPe, 
and the subsequent increased inhibition of STN neurons. This results in a decrease in the 
inhibitory output from the GPi, which effectively over activates the thalamus causing 
increased glutamatergic stimulation of the cortex, resulting in chorea (Figure 2).
Damage also extends to the nucleus accumbens, pallidum, ventrolateral thalamus, 
STN and SNpc and includes loss of cortico-striatal neurons in layer V of the cortex. When
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the disease becomes more advanced, striatal output neurons to the GPi (direct pathway) are 
affected, resulting in disinhibition of GPi neurons. The increased activity of these neurons 
has the effect of reducing chorea sometimes to the extent where hypokinetic symptoms 
such as decreased motor activity and rigidity occur (Albin et al., 1990). PET studies have 
shown reductions in both Di and D% receptor binding in the striatum of HD patients with 
both rigid and choreic predominance. Decreases of at least 40% have been found in early 
stages of the disease (Brooks, 1998). This opens the possibility of detecting pre-clinical 
features of the disease in patients carrying the HD gene.
1.3. The AS/AGU Rat
The AS/AGU rat arose as a spontaneous mutation within a closed inbred colony of 
Albino Swiss (AS) rats. The mutation is recessive (Campbell et al., 1996) and the rats have 
been isolated as a true breeding substrain. Phenotypic differences are the result of a single 
mutation. The mutant is characterised by serious movement impairments including rigidity, 
a wide staggering gait with the tendency to fall over every few steps, a slight whole body 
tremor and difficulty in initiating movement, particularly in older animals. (Clarke & 
Payne, 1994; Payne et al., 1998).
There are no obvious morphological differences between normal AS and AS/AGU 
mutants with neocortical and cerebellar areas appearing normal. Immunocytochemical 
studies, however, revealed a deficit of up to 60% in tyrosine hydroxylase immunoreactive 
cells in the SNpc of 12-14 month mutants compared with AS controls (Clarke & Payne, 
1994).
Studies by Lam and colleagues (1998), revealed significant depletion of 2-deoxy- 
glucose uptake in SNpc, STN and ventrolateral thalamus in mutants. These findings
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pointed to a wider basal ganglia involvement, possibly indicating that the indirect pathway 
might be more affected than the direct.
When whole tissue dopamine levels were measured in striatal micropunches 
(Campbell et al., 1996) using High Performance Liquid Chromatography with 
electrochemical detection (HPLC-ECD), AS/AGU mutants showed a reduction of 20-30% 
compared with the parent AS strain. This reduction does not occur until the animals are 6 
months old, which is well after the time of onset of loeomotor abnormalities. These 
symptoms can, in fact, be observed when the animals are as young as 21 days old. In-vivo 
microdialysis studies on freely moving rats have found a massive reduction of extracellular 
dopamine, as measured with HPLC-ECD, in the dorsal caudate putamen of AS/AGU rats 
aged 3 months and older, compared with control rats. Three months is the earliest point at 
which stereotaxic surgery can be confidently carried out using a standard stereotaxic atlas. 
It is possible that rats at even younger age points may have similar (if not greater) striatal 
dopamine deficits. Abercrombie and colleagues (1990) reported little change in 
extraeellular dopamine until tissue levels had fallen to around 20% of eontrol values. The 
opposite seems to be the case with the AS/AGU rat. With large dopamine reductions 
having been found in mutants younger than 6  months with extracellular studies, but not in 
whole tissue levels, it is reasonable to assume that there may be a problem with dopamine 
release in the AS/AGU rat. Indeed, pharmacological studies with dopamine release 
evoking agents such as amphetamine, as well as monoamine oxidase inhibition with 
clorgyline, and dopamine re-uptake blockade using nomifensine, seem to strengthen this 
hypothesis (Campbell et al., 2000).
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1.3.1. The AS/AGU Mutation
The agu gene encodes the brain-restricted isoform of Protein Kinase C gamma 
(PKC-y). Genetic mapping demonstrates very tight linkage between the agu mutation and a 
marker in the 3' UTR encoding region of the PKC-y gene (Craig et al., 2001). A premature 
stop codon is found in the PKC-y gene of mutant rats, which would prevent synthesis of the 
catalytic domain of the protein. The result is that the AS/AGU rat has a truncated form of 
this protein with the active component missing. Therefore PKC-y activity is completely 
abolished in this animal model.
PKC-y is a 78.4 kDa protein thought to be specifically present in high concentration 
in neuronal tissues and has been implicated in a broad spectrum of neuronal functions. 
PKC activation within nerve cells is frequently associated with the modulation of ion 
channels (Shearman et al., 1989), the desensitisation of receptors (Huganir and Greenyard, 
1990), and the enhancement of neurotransmitter release. PKC-y is one of 14 isoforms 
identified in mammalian tissues. It is known to be highly expressed in purkinje cells (PCs), 
medium sized neurons of the striatum and globus pallidus, which project to the substantia 
nigra pars reticulata, and the spinal cord (Chen et al., 1995). However, the overall 
distribution of PKC-y in the CNS remains unclear.
1.3. Aims of the Study
The purpose of this study was to look closely at the effect that these deficits might 
have on locomotor performance, how this might alter with age, and whether the 
pharmacological approach of L-DOPA replacement would restore extracellular dopamine 
levels to normal AS control values.
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MATERIALS AND METHODS
MATERIALS AND METHODS
This study consisted of two sets of experiments. In experiment 1, a study of 
locomotion in AS and AS/AGU animals was made at various ages using four tests (a) 
Inclined ramp test, (b) Mid-air righting, (c) Gait analysis and (d) Infrared movement 
analysis. Experiment 2 was an investigation into the effects of L-DOPA on the movement 
disorder and included locomotor assessment, and the measurement of striatal dopamine and 
its metabolites using in-vivo microdialysis and high performance liquid chromatography. 
Details of all chemicals and equipment used during this study are listed in appendix 2.
2.1. Locomotor Assessment
A number of studies were carried out to assess locomotion in the mutant AS/AGU 
rats and to compare them with the parent AS strain.
Initially, a total of 187 AS (control) and 176 AS/AGU male mutant rats were 
observed and scored in two simple tests of movement: a) the inclined ramp test, and b) 
mid-air righting. The rats ranged in age from 20 days to 1 year. The numbers in each age 
group are shown below.
AGE (days) AS AS/AGU
20-30 17 17
40-50 35 27
60-70 37 24
80-90 23 39
100-130 34 27
140-150 22 20
365 19 20
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2.1.1. Inclined ramp test
The rats were observed whilst walking down a series of ramps of various widths (12,
9, 7, 5, 3.5 and 1cm). Each ramp was 80cm in length and was placed at an angle of 40° into
a plastic container (150x70x20cm) that contained a deep layer of bedding medium that
served to protect the rats that fell from the ramps during unsuccessful attempts.
Figure 3 shows a rat walking down the 90mm ramp. The upper surface of each ramp was
roughened with saw-cuts to provide a good grip.
Figure 3. Inclined Ramp Test showing an AS 
rat negotiating the 9cm Ramp.
Animals were placed at the top of each ramp (starting with the broadest) facing 
downward, and scored on their ability to walk to the bottom of the ramp without falling off. 
Three attempts were allowed on each ramp. All tests were video recorded and assessed on 
playback.
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2.1.2. Mid-air righting
The same animals used in the previous test were held upside down, horizontally 
above a thick layer of bedding contained in the plastic container previously described, and 
dropped.
The ability of the animal to right itself in mid-fall and land on its feet was reeorded 
as a success. Animals landing on their back, side or head were considered to have failed the 
test. Adult animals were dropped from a height of 50cm, but rats aged less than 50 days 
were dropped from 30cm to account for their smaller size. Heights were confirmed against 
a vertical calibrated scale that formed a baekdrop for video recording.
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2.1.3. Gait analysis
Secondly, in order to make a detailed study of the effects of the mutation on normal 
locomotion in the AS/AGU rat, a computerised gait analysis system was built to determine 
the pattern of foot-floor contact and to compare it with that of normal AS animals. This 
process was undertaken in 4 steps:
1) Recording of footfall patterns using a footfall chamber and video camera.
ii) Digitizing of footfall images using a silicon graphics computer and software.
iii) Analysis of images on Kontron KS400 system.
iv ) Handling of data in Microsoft excel.
i) Footfall chamber
G lass Plate
45° Mirror 
Runway
Light Source
C over
R eflected  Image
Figure 4. Footfall chamber based on a design by Clarke (1992).
This apparatus, shown in figure 4, was constructed in-house and based on an original 
design by Clarke (1992). The 100x20x10cm plexiglass box contains an enclosed platfonn 
which has as it’s central area a 6mm thick glass plate measuring 30x10cm. The relative
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narrowness of this passage is designed to encourage the rat to walk in a straight line across 
the glass, which is the recordable part of the platform. Light from an 8-watt fluorescent 
tube is shone horizontally through the edge of the glass plate, and is totally internally 
reflected unless broken and scattered downward by the contact of a foot on the glass. Pad 
to glass contact is thus represented by a white pattern which is recorded onto a videotape 
via a 45° mirror. The resulting monochrome image - white areas against black (unlit) glass 
- is vital in achieving separation of individual pads during subsequent analysis. All footfall 
recordings were canied out in a quiet, dark room. Each rat was placed onto one end of the 
platform, and at least 3 spontaneous, complete crossings of the glass area were recorded. 
Rats aged 9 months were assessed (AS n=9, AS/AGU n=9).
ii) Digitization of video images
The hind foot of the rat contains 11 pads: 5 digital tips (1,2,3,4 and 5), 4 distal pads 
(A, B, C and D) and 2 proximal pads (E and F- see figure 5a)
a) b)
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Figure 5. Diagrams showing the pad arrangement on the hind left foot o f a rat. a) The 11 pads are labelled: 5 digital tips 
(1,2,3,4 and 5), 4 distal pads (A, B, C and D), and 2 proximal pads (E and F). b) The foot is divided along the mid- 
anterior/posterior line in order to determine lateral and medial groupings.
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The videotape was viewed frame by frame, and the frames were digitized using a 
silicon graphics workstation to obtain individual images throughout each step taken by 
both the left and right hind feet. This resulted in a set of images per step ranging between 6 
and 20 in number depending on speed of movement (see figure 6 ). Only steps falling 
within this range were considered, in order to ensure that the speed was neither too slow 
nor too fast. This helped to ensure consistency and accuracy.
The images were then saved in a form (.bmp) that could subsequently be handled by 
the imaging software.
Figure 6. Sets o f digitised images o f  pad-floor contact from the start, middle and end o f a typical step.
a) The AS rat starts the step with all pads in contact with the glass and is linear throughout the step.
b) The AS/AGU begins with incomplete contact and continues through the step with abnormal contact and 
with the foot at an angle.
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iii). Image analysis
A Kontron KS400 image analysis system was used to a) process footfall images into 
a binary form which was necessary for automatic measurements, b) present the images to 
be interactively separated into individual pads, and c) measure the area of contact o f each 
pad, and display these areas.
iv). Data handling
Data was transferred directly into Microsoft Excel. Pad areas from the whole foot 
were divided into 2 groups, ie., those pads falling in the lateral half of the foot (1, 2, A, B 
and E), and those of the medial half (4, 5, C, D and F). The foot was divided along the mid- 
anterior/posterior line in order to determine the groupings (figure 5b).
Areas within both segments were added together to give total values for lateral and 
medial sides that were then expressed as percentages of the whole foot contact area.
2.1.4. Infrared movement analvsis
A third study was undertaken to evaluate normal spontaneous locomotor activity 
within the cage environment, using the computerised infrared sensor system which is 
shown in figure 7.
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This equipment, a Coulbum Instruments infrared motion activity system, is capable of 
detecting movement within the cage in three dimensions, and recording information about 
the number and duration of movements based on pre-programmed criteria.
Figure 7. Cages with sensors which detect spontaneous locomotor 
activity as part o f the infrared movement monitoring system.
An infrared sensor is attached to the top of a cage of dimensions 50x32x18 (cm) 
facing into the cage at an angle of 45° to ensure that activity in all areas of the cage is 
detectable. The sensors are connected to a computer software package from which data can 
be collected
AS control and AS/AGU male rats aged 9 and 12 months (n=9 for each strain in 
each age group) were assessed. Activity was monitored over two different time periods: a) 
a 12-minute run, with data being reported every minute, and b) A 22-hour run, which 
reported every 15 minutes. Movements of two different durations were recorded ie: small 
movements (1-3 seconds duration), and large movements (more than 3 seconds). This 
ensured that movements lasting less than 1 second would not be reported. In this way 
natural phenomena such as breathing, or tremor in the case of mutants, were ignored.
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2.2. L-DOPA treatment
This consisted of two studies. One to examine the effects of L-DOPA on 
locomotion, the second to evaluate the effect of L-DOPA administration on dopamine 
release in the striatum.
2.2.1. Locomotor assessment
Twenty AS/AGU animals aged three months were used to assess the effects on the 
locomotor disorder of the classic Parkinson’s drug L-DOPA which can cross the blood- 
brain barrier and is therefore given instead of dopamine. Rats were divided into 2 treatment 
groups with 10 in each group. One group was treated with L-DOPA and the other with 
saline as a control injection. Animals in the drug treatment group were given 
intraperitoneal injections of L-DOPA (25mg/kg in 1ml of saline) daily for 4 weeks. Each 
injection was preceded hy an injection of the peripheral DOPA decarboxylase inhibitor 
benserazide (2.5mg/kg in saline) 30 minutes prior to L-DOPA treatment. This ensured that 
the administered L-DOPA was being metabolised in the brain only. All treatments were 
given at the same time point each day.
Mid-air righting and inclined ramp tests as described above were carried out at 
weekly intervals on all animals, two hours after the L-DOPA or saline injections. Testing 
was restricted to one session per week in order to minimise learning effects.
2.2.2. Measurement of extracellular levels of Dopamine. DOPAC and HVA in the 
striatum.
Microdialysis, followed by high performance liquid chromatography with 
electrochemical detection (HPLC-ECD), was used according to the method adopted by 
Campbell et al. (1998), in order to determine extracellular levels of dopamine and its
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metabolites in the striatum in freely moving rats. This technique allows the monitoring of 
normal basal neui’otransmitter levels in conscious animals, and also has the benefit of being 
able to show the effects of drugs administered either before or during the micro dialysis 
process. Samples can be collected at chosen flow rates thus determining sample volume, 
and neurotransmitters can be detected at very low concentrations (picomoles) in protein 
free samples. This eliminates the need to pretreat samples before HPLC analysis.
There are three main stages to the extracellular sampling study; i) implantation of a 
guide cannula, ii) collection of microdialysis samples via a probe, and iii) HPLC-ECD 
analysis.
After the four week L-DOPA treatment described above, 4 AS and 4 AS/AGU rats 
were studied using these techniques, under Home Office project licence 60/2167.
i) Implantation of cannula.
This procedure was carried out by Dr Jackie Campbell under the above licence. 
Animals were anaesthetised using Vetalar (ketamine hydrochloride; lOOmg/ml) and 
Rompun (Xylazine hydrochloride 2%) in a ratio of 2:1. Intraperitoneal Injections were 
given at 1 .1 ml/kg of body weight.
Deep anaesthesia was achieved after 5-10 minutes. The 'toe pinching' technique was 
used to determine this, with no reflex withdrawal of the foot being observed when full 
anaesthesia was established. The animal was then placed into ear bars on a Kopf 
stereotaxic frame, and the head held in place using tooth and nose bars. This stabilised the 
head to allow a midline incision to be made in a pre-shaved area of the scalp using a 
scalpel blade, the skin being held back from the skull using skin retractors.
Scraping of the skull using a scalpel blade revealed the point of intersection of the 
coronal and sagittal cranial sutures (bregma), which was marked using a pencil.
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Coordinates derived from a standard atlas of the rat brain (Paxinos and Watson, 1982), 
were used to locate the dorsal caudate-putamen. These coordinates were; 1mm 
(anterior/posterior), 3.5mm (lateral) and 4.5mm (ventral), using bregma as a starting point. 
This is shown in 
figure 8 .
Figure 8. Diagram a brain section showing the level o f  the striatum from which 
microdialysis samples were taken. The grey circle indicates the dorsal sampling 
point which is represented by the coordinates: 1mm (anterior/posterior), 3.5mm 
(lateral) and 4.5mm (ventral). From ‘The rat brain in stereotaxic coordinates’ 
(Paxinos and Watson, 1982).
Firstly, the anterior/posterior and lateral coordinates were used to determine the 
point on the skull into which a hole was drilled using a 1mm drill. The cannula was then 
placed over and lowered into the hole slowly until the ventral coordinate was reached.
In order to ensure that the cannula would remain in place until the end of the 
experiment, it was secured using Redifast dental cement. A further two holes were drilled 
into the skull in an area close to the probe, into which two screws were placed securely 
before the cement was poured over the whole area which was contained within a plastic 
‘hat’ which was made by cutting a 5ml plastic syringe to obtain a 1cm deep cylinder. Being
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embedded in the eement, the screws had the function of ensuring that the cannula assembly 
was properly secured onto the rat’s head.
Once the cement hardened, a guide cannula was placed inside the previously 
inserted cannula in order to seal and protect it from damage. The rat was then removed 
from the stereotaxic frame, a subcutaneous injection of 0.1ml Antisedan (atipamezole 
hydrochloride, 5mg/ml) was given to reverse the effect of the anaesthetic, and the animal 
was allowed to recover in an incubator before being placed back into its cage.
This whole procedure had to be performed within a 40 minute period in order to 
ensure that the animal did not recover before the operation was complete. The position of 
the cannula was confirmed at a later date by sectioning the brain on a Jeol cryoststat.
ii) Microdialvsis
After a period of two days recovery in their normal cage environment, animals were 
linked up to a microdialysis system. This consisted of a CMA automatic microinjector, a 
series of lengths of narrow bore tubing, a microdialysis probe and a Perspex box 
(42x23x41cm). The Perspex box contained rat bedding material, food and water, and had a 
metal lever (reflex arm) attached which allowed the rat to move around the box freely 
without disrupting the tubing or probe.
The rat was held securely with its head immobilised, and the probe was then 
inserted carefully into the cannula, and secured with superglue. The microsyringe was 
attached to the probe’s inflow tubing via a connection at the collection port that was 
situated at the end of the reflex arm. The outflow probe tubing was connected to a plastic 
collecting vial at this port.
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The microdialvsis probe
Outlet Intlet
\  y
D ialysis | 
Membrane -I I
Figure 9. Single cannula type probe 
used to collect microdialysis samples.
Based on a method by Carswell et a l, (1997),
Shown in diagram 9, the microdialysis probe is a single cannula type and is a 
variation on that used by Carswell and colleagues (1997). It consists of a series of tubing 
types of different diameters ranging from a 1mm diameter plastic tube down to a silica 
glass tubing which is situated innermost in a concentric arrangement, and has an outer 
diameter of 25 p,m.
The probe’s active area, which forms the tip, consists of a 200pm ID semi 
permeable tubular dialysis membrane with a 40,000 molecular weight cut-off. The pore 
size is 60Â. Microdialysis occurs over the exposed surface of this membrane, and its length 
can be adjusted to suit the size of the brain area under investigation. Artificial 
cerebrospinal fluid (ACSF) flows into the region where the microdialysis takes place and 
the dialysed liquid then flows back out of the probe, via the silica glass tubing that is 
situated inside the microdialysis tubing, the tip of which is plugged with RS epoxy resin.
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The dialysis membrane allows the two-way passage of fluid with the exclusion of any high 
molecular weight protein matter that would contaminate the sample. Neurotransmitters are 
thus passed through a concentration gradient into the transmitter- free ACSF. This allows 
us to monitor basal extracellular concentrations under standardised conditions as well as 
following pharmacological interventions. This fluid is passed through the probe at a flow 
rate of 2 pl per minute via a length of narrow bore perspex tubing (0.28mm internal 
diameter) and is collected after microdialysis in the plastic collecting vial. Samples are 
collected eveiy 20 minutes giving a sample volume of 40pl. No pre-HPLC treatment is 
required for these pure samples, hence they can be either injected onto the HPLC system 
immediately or frozen in liquid nitrogen for injection at a later time.
Animals were allowed to move around freely in the Perspex box for a period of 
between 1 and 2  hours before samples were collected, and after a series of 3 consistent 
samples showing steady neurotransmitter levels, basal sample collection began. Basal 
samples (resting levels after 4 weeks of L-DOPA treatment) were collected for a period o f 
100 minutes before a bolus injection of Benserazide (lOmg/kg in 0.1% sodium bisulphite) 
and L-DOPA (lOOmg/kg in sodium bisulphite) were given half way during the collection 
of the last basal sample. Samples were then collected for a further 5-hour period.
i) HPLC-ECD analvsis
Sample analysis was carried out according to the method used by Campbell et al 
(1998). The HPLC system consisted of a Gilson 305 pump with 805 manometric module, a 
71251 Rheodyne sample injector, a microbore column and an ANTEC intro 
electrochemical detector. The column (stationary phase) was a Hichrom microbore reverse 
phase column with a C l8 ODS2 5pm packing gel. This allowed effective and consistent 
separation of catecholamines when used with a buffered mobile phase consisting of: Citric
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acid (83 mM), EDTA (ImM), Disodium Hydrogen Phosphate (43 mM), Octane Sulphonic 
Acid (0.2 mM) and Methanol (10%). PH was 3.5.
A lOOpl sample loop was used on the injector to ensure that the whole sample 
(45pi) was injected onto the column. This maximised the amount of detectable 
neurotransmitter.
A composite standard containing all of the detectable metabolites (Dopamine, 
DOPAC, 5HT, 5HIAA and HVA) was prepared at a concentration of 10 nanograms per ml. 
for each. An internal standard, 3,4,dihydroxybenzylamine (DHBA), was added to the 
composite mixture at the same concentration. This composite mixture has two functions. 
Firstly, it is used to determine the time that it takes each substance to be eluted from the 
column, and detected by the ECD (retention time). Secondly, the peak areas from the 
resulting composite chromatogram are used to calculate the response factor (RF) for each 
substance. This factor (DHBA peak area divided by area of transmitter peak), is later used 
when calculating final concentrations.
A typical 45 pi microdialysis sample contains 40pl of dialysate and 5 pi of DHBA at 
the same concentration as in the composite standard. With some experiments, a sample 
volume of slightly less than 45pi was injected due to a smaller return per 20 minutes via 
the microdialysis probe. The 5 pi of DHBA (internal standard) was added in order to obtain 
a peak from each sample that represented a knovm concentration. This internal standard 
was chosen because it is stable, is not found in the brain, and it is not known to react with 
any of the catecholamines present in the sample. This peak area for DHBA was used to 
calculate the unknown concentrations of catecholamines within the sample. These were 
expressed in picograms per sample.
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Typical composite standard and sample chromatograms are shown in Figures 10a) and b).
a)
1000 -
0 -
0 10 20
Time (minutes)
b)
1000 -
0 -
0 10 20
Time (minutes
Figure 10. Typical HPLC chromatograms from a) Composite standard, and b) Microdialysis sample. Peaks in 
order o f elution are DHBA (internal standard). Dopamine, DOPAC, 5HT, 5H1AA and HVA (not in this 
sample).
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These chromatograms show the order of elution of the internal standard and 
neurochemicals under investigation. The catecholamine peaks are identifiable by their 
retention times, a line drawn underneath the peaks, and the areas calculated by the 
computer software. The calculation by which the peak concentrations are determined from 
these areas is shown in appendix 1 .
2.3 Statistical Analysis
In both the age series study and the L-DOPA investigation, performance on the series 
of ramps of decreasing width was analysed statistically using analyses of variance (F). 
Ramp width constituted a non-continuous variable in the analysis. With mid-air righting 
tests, comparisons were carried out using chi square tests. All of the remaining 
statistical analyses were performed using Student’s t-tests.
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RESULTS
RESULTS
3.1. Locomotor Assessment
3.1.1. Inclined ramp test
The results of the inclined ramp test are shown in Figure 11.
AS animals
As shown in figure 11a, AS control animals in all of the age groups tested performed 
well across the range of ramp widths except for the narrowest (1cm), where the percentage 
of rats completing was found to be reduced as the animals got older and bigger. This 
resulted in only 60% success from age 100 days. This figure is reduced to a 10% success 
rate by 1 year of age. Performance on the second narrowest ramp (3.5cm) was also 
affected, but to a much smaller degree. Here, 80% of rats at 1 year still managed to walk 
down the ramp without falling off.
AS/AGU animals
The general pattern seen in figure 1 lb) is of a decline in performance on all ramp 
widths with age. No AS/AGU rat tested, regardless of age, was able to successfully walk 
down the 1cm ramp. None of the mutant rats aged 50 days or older were able to negotiate 
the 3.5cm ramp with any success. There was also a very poor success rate (maximum 10%) 
on the 5cm ramp after 50 days.
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Performance according to age was analysed for both the AS and AS/AGU groups by 
analyses of variance (F); see Appendix 3a. Because ramp width constituted a non- 
continuous variable, each ramp was assigned a score from 1 (the narrowest) to 6  (the 
widest). Each animal at each age received a score in this range which was therefore the 
narrowest ramp it was capable of negotiating successfully; an animal which could not walk 
down any ramp received a score of 7. Both groups of animals showed a highly significant 
variance in performance with age. For AS males (F ^  33.23, df 5 x 158, p < 0.001) and 
AS/AGU males (F = 35.17, df 5 x 129, p < 0.001) in which there was an increase in the 
narrowest ramp they were capable of walking down. However, in the case of AS rats, this 
simply meant that performance declined from all rats being capable of negotiating the 
narrowest ramp (1cm) to most rats only being able to negotiate the second narrowest ramp 
(3.5cm). Performance at the earliest three ages did not differ significantly, but animals aged 
100-130 days had a significantly poorer performance (p < 0.05), whilst animals aged 140- 
150 days and 365 days exhibited a poorer performance than all younger animals (p < 0.05). 
In the case of AS/AGU rats, performance declined much more drastically (from most 
animals being able to negotiate the third narrowest ramp at 20-30 days to very few animals 
being able to walk down even the widest ramp at 365 days). Thus, performance at 40-50 
days was significantly worse than at 20-30 days (p < 0.05); performance over the age range 
of 60-150 days was worse still (p < 0.05) and performance at 365 days was worse again (p 
< 0.05). For each age, comparisons between AS and AS/AGU rats were made by t-tests 
(see Appendix 3b); in each case these revealed a highly significant difference between the 
two strains with locomotor performance being worse in the AS/AGU group (p < 0.001). 
Comparisons could not be made for the youngest group (20-30 days) because all AS rats 
could negotiate all ramps and therefore there was no variability in the data.
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The general decline for the remaining 3 ramp widths (7, 9 and 12cm) resulted in the 1 year 
animals having no success on any ramp except for the small number (2 0 %) that managed to 
complete the task on the broadest ramp.
100
■o
1
Q.
Eoo
Q)O)
S
C0>
2 0) 
Q.
50
20-30 40-50 60-70 100-130 140-150 365
B
100
■o
1
Q.
EoÜ
0)O)
2  c m
2a>Q.
50
I m
20-30 40-50 60-70 100-130 140-150 
Age (days)
B 1cm
B 3.5cm
□ 5cm
□ 7cm
B 9cm
□ 12cm
365
Figure II . Inclined Ramp Test
1 he percentage o f  AS and AS/AGU rats capable o f walking down inclined ramps o f various widths is shown as a 
function o f age up to one year.
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3.1.2. Mid-Air Righting 
AS animals
Figure 12 shows that the majority of AS control rats throughout the age groups 
tested were able to turn in mid-air and land on their feet. Excepting the one-year age group, 
all animals showed at least a 90% success rate. One year old AS control rats righted in 
mid-air less consistently, although over 70% still managed to land in an upright position.
AS/AGU animals
AS/AGU rats, shown in figure 12, proved to be much less capable than AS controls 
with this task. The youngest animals tested showed only a 60% pass rate. This tailed off 
gradually as older animals were tested, with 80% of mutants at 140 days showing an 
inability to land on their feet. By the age of 1 year, no AS/AGU rat was able to right in 
mid-air.
100
□  AS/AGU
0  H— — —1—^ —I— — —I— — —I— — —[— — —I— ------ 1
20-30 40-50 60-70 80-90 100-130 140-150 300-365
Age (days)
Figure 12. Mid-air Righting
The percentage o f AS and AS/AGU rats capable o f  righting in mid-air is shown as a function o f age up to one year.
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Comparisons between the ability of AS and AS/AGU rats to right in mid-air were carried 
out using chi-square tests. The results of these are shown in Appendix 4, from which it
can be seen that the two strains differ at all the ages tested. In each case, performance of
AS/AGU animals was worse than AS controls.
3.1.3. Gait analysis
Footfall patterns were recorded from the left and right hind feet of 9 month AS (n=8 ) 
and AS/AGU (n=7) rats. Up to 4 recordings were digitized from each animal, depending on 
their willingness to cross the recordable area of the apparatus. Initially, the approach taken 
by Clarke (1992) was used whereby footfalls were analysed on an anterior/posterior basis, 
with the footfalls being divided into 3 zones.
Zones were arranged thus (see figure 6 a):
A - Pads 2, 3 and 4 
B - Pads 1, 5, B and C 
C - Pads A, D, E and F
This arrangement was designed by Clarke (1992) to assess weight distribution in the 
anterior-posterior plane as the animal walked freely. In the present study, however, it 
became clear from observing movement in the rats, that this method of assessment of 
weight distribution would not be the best approach as thy tend to stagger from side to side. 
As an alternative, foot contact was analysed across the foot in a medial-lateral plane. This 
established a difference between AS control and AS/AGU mutant footfalls.
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Computed gaits were compared between AS and AS/AGU rats in several ways.
■ First of all, the "best" footfall of each rat was compared in the two strains. In this case, the 
notion of "best" is that closest to a "perfect" footfall in which weight distribution (averaged 
over the period of contact) is 50% on either side of the mid-line of the foot. From 
Appendix 5 (a) it can be seen that the two groups did not differ in this measure.
- Secondly, the "worst" footfall of each rat was compared in the two strains. In this case, 
the notion of "worst" is that furthest from a "perfect" footfall as defined above. From 
Appendix 5(b) it can be seen that the two groups differed significantly in this measure (p <
0.05) with the AS/AGU rats diverging considerably from the perfect footfall.
■ Thirdly, the difference for each animal between "best" and "worst" footfalls (as defined 
above) in analysed in Appendix 5(c). From this it will be seen that the two groups differed 
significantly in this measure (p < 0.05) which was much greater in the AS/AGU rats than in 
AS ones.
Shown in figure 13, is the percentage lateral contact (area of foot/floor contact made by the 
lateral side, expressed as an average of total contact) for all footfalls analysed in the study. 
Thus, 100% laterality would be found if an animal walked on the lateral edge of it’s paws, 
0% laterality if it walked on the medial edge. Taking paw contact overall, AS control 
animals did not show extremes of contact in either a lateral or a medial direction and most 
footfalls were grouped around the central (50%) point. Indeed the mean for control animals 
was 53.19 and the standard deviation was 8.58.
44
The central coloured bands in the chart represent one and two standard deviations either 
side of the mean for the normal control animals (ie 34% and 96% respectively, of control 
values). It can be seen from this chart that a large number of mutant footfalls fall outwith 
this band, and many show excessive contact of either lateral or medial sides of the foot. 
This was in excess of 80-90% in the worst cases.
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Figure 13. Gait analysis
Footfall contact shown as percentage contact made by the lateral side o f the foot for both left and right feet.
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In Figure 14, the same set o f footfalls is organised into 3 footfall types:
100
50
One Standard Deviation
E]
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AGU
Two Standard Deviations
S) ■  Type 1 - Central
□  Type 2 - Lateral !
□  Type 3 - Media! side
c ^  side
AS AGU
Figure 14. Gait analysis
Footfall contact in show n as percentage o f  each o f  three footfall types after one(a) and tw o(b) standard 
deviations.
Type 1 - Footfalls falling within the first and second standard deviation bands from Figure 
13.
Type 2 - Outwith these bands and weighing on the lateral side.
Type 3 - Outwith these bands and weighing on the medial side.
32% of control footfalls lie outside the Ix standard deviation band (and 4% outside the 2x 
standard deviation band). Using these same control means and standard deviations, it can 
be seen that 67% of mutant footfalls lie outside the control 1 x standard deviation band (and 
40% outside the 2x standard deviation).
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3.1.4. Infrared Movement Analysis
In general, AS/AGU mutants were more active under the testing conditions than 
normal AS controls. When spontaneous movement was measured over the shorter time 
span of 12 minutes (Figure 15), AS/AGU rats aged both 9 and 12 months made more 
movements in both small and large categories. Comparisons were made between both 9 
month and 12 month male AS and AS/AGU rats for both small and large movements, in 
both 12-minute and 22-hour sessions. The results of these are shown in appendix 6 . There 
was no significant difference between the groups tested in the 12-minute sessions. Over 22 
hours the result is different, with significant differences being found between the two 
strains at both age points, for both small and large movements (P=<0.05 in all cases), 
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Figure 15. Infra-red movement analysis
Number o f  spontaneous small and large movements made by 12(a) and 9(b) month AS and AS/AGU rats 
during a 12-minute test period. Bars are standard errors.
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The same pattern was observed in both age groups during the 22-hour sessions (Figure 16).
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Figure 16. Infra-red movement analysis
Number o f  spontaneous small and large movements made by 12(a) and 9(b) month AS and AS/AGU rats 
during a 22-hour test period. Bars are standard errors.
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3.2. L-DOPA treatment
3.2.1. Inclined ramp test
Figure 17 shows that in AS controls, no difference was seen between saline and L- 
DOPA administration, ie., all rats showed maximum performance with both treatments.
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Treatment
Figure 17. L-Dopa treatment: Inclined ramp test.
Fhe eMeets o f saline or L-Dopa on the ability o f  AS rats aged 3 months to walk down inclined ramps o f 5. 7 and 9cm 
widths. Weeks 3 and 4 are shown.
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Figure 18 shows the effects of dopamine replacement by L-DOPA administration in 
AS/AGU animals after weeks 3 and 4 of the experiment. Although the animals were tested 
on their ability to negotiate all 6  ramp widths as in the previous experiment, only 5, 7 and 
9cm ramps are shown here, for simplicity, this being the range within which improvement 
due to the action of the drug was observed. In the third week of treatment the narrowest 
ramp successfully negotiated by a saline treated AS/AGU rat 9cm wide whereas L-DOPA 
treated mutants were successful on both 9cm (60%) and 7cm (50%).
By week 4, performance on the aforementioned ramps had increased to 90% and 
80% respectively for L-DOPA treated animals. Moreover, 60% of this group were able to 
complete the 5cm ramp by this stage.
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Figure 18. L-Dopa treatment: Inclined ramp test.
The effects o f saline or L-Dopa on the ability o f  AS/AGU rats aged 3 months to walk down inclined ramps o f 5. 7 and 
9cm widths. Weeks 3 and 4 are shown.
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Performance in the Inclined Ramp test was analysed for the AS/AGU males treated with 
saline or L-DOPA groups by a two-way analysis of variance (F); see Appendix 7a. As has 
been discussed in the age series results section, because ramp width constitutes a non- 
continuous variable, each ramp was assigned a score from 1 (the narrowest) to 6  (the 
widest). Each animal received a score in this range which was therefore the narrowest ramp 
it was capable of negotiating successfully; an animal which could not walk down any ramp 
received a score of 7.
However, it rapidly became clear
That drug effects could not be seen prior to the third and fourth weeks of testing 
■ That the greatest changes were in the ability of animals to negotiate the planks of 
middling width, viz. 5, 7 and 9 cm wide.
A two-way analysis of variance (Appendix 7a) was therefore carried out on AS/AGU rats 
to compare a) the performance on weeks 3 and 4, and b) the treatment received (saline or 
L-DOPA). Appendix 7a reveals that there was a highly significant variance for both 
treatment and week of treatment.
Student's t-tests were carried out between the performance of saline and L-DOPA treated 
males on the two weeks concerned. The differences did not reach significance on Week 3, 
but did on Week 4 (p < 0.01) with L-DOPA treated males having a better performance than 
saline-treated ones (see Appendix 7b).
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3.2.2. Mid-Air Righting
Figure 19 shows that in AS controls, no difference was seen between saline and L- 
DOPA administration, ie., all rats showed maximum performance with both.
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Figure 19. L-Dopa treatment: Mid-air righting.
The effects o f saline or L-Dopa on the ability o f AS rats aged 3 months to right in mid-air.
The percentage of saline and L-DOPA treated AS/AGU rats capable of mid-air righting 
throughout the course of the treatment is shown in Figure 20. On the first week of 
treatment, both saline and L-DOPA treated animals had similar rates of success (around 
25%). Improvement in performance was subsequently observed only in the L-DOPA 
group, which showed a steady increase as the trial progressed, reaching a high of 90% by 
the fourth week.
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The effects of L-DOPA on mid-air righting performance in AS/AGU rats compared to 
AS/AGU rats treated with saline were analysed by chi-square (%^ ) tests. These can be seen 
in Appendix 8 . Whereas there are no differences after either one or two weeks of treatment, 
there are significant differences in the numbers of animals carrying out mid-air righting 
successfully at three and four weeks of treatment (p < 0 .0 1 )
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Figure 20. L-Dopa treatment: Mid-air righting.
The effects o f  saline or L-Dopa on the ability o f  AS/AGU rats aged 3 months to right in mid-air.
3.2.3. Measurement of extracellular levels of Dopamine. DOPAC and HVA in the 
striatum.
Previous work on the AS/AGU rat has shown vastly reduced levels of extracellular 
dopamine in the dorsal caudate putamen as measured in dialysates by HPLC/ECD 
(Campbell et al. 1998). These dopamine levels are shown as the first part of Figure 21a).
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Figure 21. L-Dopa treatment: Comparison o f levels o f extracellular dopamine(a), DOPAC(b) and HVA(c) obtained by 
microdialysis and HPLC/ED, before and after L-Dopa treatment. Bars are standard errors.
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From figure 21 it can also be seen that in both AS and AS/AGU strains, “resting” 
dopamine levels obtained 24 hours after the last L-DOPA injection, are almost twice those 
found in saline treated rats. Dopamine levels taken after the administration of a 1 OOmg/kg 
bolus injection are also shown. Average dopamine levels found during the period between 
the injection and the termination of the experiment, and peak levels during this period, are 
represented in bands c) and d) respectively.
It can be noted from these average and peak levels that there is a significant 
increase for both AS and AS/AGU animals compared with their “resting” levels, and that 
dopamine levels in the mutant almost reach those of untreated AS controls animals. 
Analysis of variance over the three L-DOPA treatment groups was highly significant 
(F=496, df 5x18, p<0.001), and inter group comparisons using Confidence Intervals 
showed that both peak and mean dopamine values after bolus injection were significantly 
higher than pre-administration ‘resting’ levels in both AS and AS/AGU rats (p<0.05 for 
all).
Figures 21b) and 2Ic) show the same treatment groups as in figure 21a). In 
previous experiments, low levels of extracellular dopamine have been combined with 
greatly increased levels of the dopamine metabolite DOPAC, and relatively unchanged 
levels of HVA (Campbell et al. 1998). Twenty-four hours after the last injection of L- 
DOPA (25mg/kg), the level of DOPAC was found to be about double that of untreated 
basais, with HVA being largely unchanged. After the 1 OOmg/kg bolus injection, however, 
striatal concentrations of both metabolites had significantly increased in average (c) and 
peak (d) levels. Analysis of variance over the three L=Dopa treatment groups was highly 
significant (for DOPAC F=428, df 5x18, p<0.001; for HVA F=568, df 5x18, p<0.001), and 
inter group comparisons show that both peak and mean dopamine values after bolus 
injection were significantly higher than pre-administration ‘resting’ levels in both AS and
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AS/AGU rats (p=0.05 for all). Figures 23a), b) and c), are time course graphs that follow 
sample collection from initial L-DOPA resting levels, through the bolus injection to the 
end of the experiment. This covers a time span of over 6  hours.
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Figure 22. L-Dopa treatment: Time course of extracellular levels of dopamine(a), DOPAC(b) and 
HVA(c) obtained by microdialysis and HPLC/ED, before and after L-DOPA treatment, over a four 
hour period. The arrow marks the time of bolus injection. Bars are standard deviations.
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The time of bolus injection administration (BlOO), is shown by an arrow. AS control 
dopamine values reach a peak level 40 minutes earlier than those of mutant animals, and 
whilst AS values do not return to resting levels by the end of the experiment, AS/AGU 
resting levels are restored after about 100 minutes. Levels of both DOPAC and HVA 
remain elevated throughout the post-bolus period in both Control and mutant animals. It 
should be noted that figure 2 2  illustrates the time course of extracellular release of 
dopamine, DOPAC and HVA in the L-DOPA experiment and does not include any 
statistical analysis. This analysis is to be found in appendix 8 and figure 21.
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DISCUSSION
DISCUSSION
The discovery of a naturally occurring, spontaneous mutation in the Albino Swiss 
colony at Glasgow University created a whole series of research possibilities. It was soon 
established that physical characteristics of this mutant, such as difficulty in initiating 
movement, whole body tremor, a wide staggering gait and the inability to walk even a few 
steps without falling over, along with the finding of a reduced number of dopaminergic 
neurons in the SNpc (Clarke and Payne, 1994), made it a potentially valuable model for a 
Parkinson’s like movement disorder. Its advantages over existing toxin induced models 
such as those using 6 -Hydroxydopamine (Ungerstedt, 1968; Sakai and Gash, 1994) or 
MPTP (Moratalla et al., 1992; Herrero et al., 1993; Gnanalingham et al., 1995) were clear 
in that the progressive nature of the disorder could be monitored closely from the earliest 
onset of locomotor symptoms through to the advanced stages where locomotor and 
neurochemical deficits would be most pronounced. The possibility of gaining insight into 
the genetic aspects of a condition that displayed the symptoms of a hypokinetic movement 
disorder was also an exciting prospect.
The need to devise a series of simple, robust locomotor tests was an early priority, 
in order to assess and characterise the physical nature of the mutation. This would form a 
basis for future therapeutic investigations.
4.1. Locomotor Assessment Techniques
Locomotor and other behavioural testing have been used in the assessment of 
laboratory animals such as rodents and non-human primates for many years. Various 
methods have been used in the attempt to assess and quantify a variety of abilities in a) 
normal control animals b) animals that are being screened for the physical effects of
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administered toxic substances such as 3-Acetyl pyridine and acrylamide (Jolicoeur et a l,
1979) and pp-iminodipropionitrile (Ivens, 1990) and c) mutant animals with locomotor 
dysfunction such as the shaker rat, which has deficits in the purkinje cells of the cerebellum 
(Wolf et al., 1996), or the weaver mouse which has both cerebellar and dopaminergic 
deficits (Eisenman et al., 1998). There has also been much use of locomotor testing in 
models of Parkinson’s disease such the rat 60HDA model (Sakai and Gash, 1994; Borlogan 
et al., 1996; Mukhida et al., 2001), and in non-human primates (Herrero et al., 1993; 
Gnalalingham et al., 1995; Moratalla et al., 1992) and in mice (Rosas et al., 1998; 
Fredriksson et al., 1990; Nishi et al., 1991) with MPTP lesions.
Spontaneous locomotor activity, usually in a cage environment, has been monitored 
in most of the aforementioned studies and interpreted as a good indicator of general motor 
activity. The effects of drugs, toxins and genetically-induced locomotor deficits can then be 
quantified over time, and depending on how sophisticated the monitoring system is, 
various parameters such as number, duration speed and direction of movement can be 
measured (Borlogan et al., 1996; Doan et al., 1999; De Leonibus et al., 2001; Mead et al., 
1994)
Apart from non-specific spontaneous locomotion, a wide range of other simple tests 
have been devised. These include hand gripping tests, which have been used on monkeys 
(Rouiller et al., 1998; Lemon et al., 1996) and also on rodents (Colotta et al., 1990; Ivens, 
1990; Gad, 1982) to assess motor control of fingers. Forelimb and hindlimb placement 
(Wolf et al., 1996); the ability to walk along a rod, right in mid-air and on a surface (Wolf 
et al., 1996; Gad, 1982).
Another common method in the study of locomotor deficits is the measurement of 
gait parameters in normal walking patterns. Apart from the use of the footfall chamber in 
determining pad-floor contact areas (as used in this study), other parameters such as stride
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length, gait width, and gait symmetry have been used to quantify abnormal gait patterns. 
(Wolf et al., 1996; Domer et a l, 1996; Jolicouer et a l, 1979; Parker and Clarke, 1989).
The use of the Morris water maze whereby an animal is tested on its ability to swim 
to and find an underwater platform (Setlow and McGauch, 1999) involves movement and 
spatial memory. In the case of the AS/AGU rat, cognitive tests such as the water maze have 
yet to be carried out.
The rotorod, a revolving cylinder with adjustable speed, has proven to be a useful 
test of hind and forelimb dexterity, motor function and co-ordination. Rodents are tested on 
their ability to remain on the rod for set time periods as the speed of rotation is increased 
(Ivens, 1990; Colotta et a l, 1990; Rozas et a l, 1998). This useful but relatively expensive 
equipment has not yet been acquired for use with the AS/AGU mutant.
As mentioned before, models of movement disorders which involve the selective 
destruction of dopaminergic neuions and systems have proven to be useful in gaining 
understanding of the mechanisms of neurodegeneration in diseases such as Parkinson’s 
disease. The development of pharmalogical approaches to these diseases, and an improved 
understanding of the functional anatomy and physiology of the basal ganglia are also major 
benefits derived from these models. Locomotor and behavioural testing has played an 
important part in reaching these findings.
Bilateral injection of 60HDA into the striatum causes akinesia, aphagia and adipsia 
with increased mortality (Ungerstedt, 1968; Sakai and Gash, 1994). Unilateral lesions, 
however, have allowed the use of behavioural testing in the form of the assessment of 
rotational behaviour. After lesioning, these rats show normal behaviour, and circling occurs 
only when drugs affecting the dopaminergic system are given. Rotations contralateral to the 
lesioned side occur when dopamine agonists such as apomorphine are administered, 
whereas circling which is ipsilateral to the lesioned side is caused by dopamine releasing
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drugs such as amphetamine (Borlongan et a l, 1996; Mukhida et al., 2001; Hefti et al.,
1980). This so called ‘UngerstedT model is potentially useful in testing novel anti­
parkinsonian drugs. Behavioural improvements after unilateral 60HDA lesions have been 
reported with the use of L-DOPA (Sakai and Gash, 1994) and dopaminergic transplants 
(Mukhida et al., 2001). In the AS/AGU rat, the assessment of rotational behaviour is not a 
relevant testing method as the dopaminergic deficits in these animals are usually bilateral 
in nature. There may be some scope, however, in the use of 60HDA in future AS/AGU 
studies in order to investigate the effects of apomorphine and amphetamine on behaviour in 
rats with natural bilateral lesions.
MPTP is used mainly in non-human primates and in mice, and does not appear to 
be effective in rats. Its action causes parkinsonian-like motor symptoms. Rozas and 
colleagues (1998), suggest the rotorod as being an excellent method for testing basal 
locomotor capacity in MPTP treated mice, as well as the effects of treatments such as L- 
DOPA and apomorphine. L-DOPA has also been used in reversing MPTP-induced 
hypoactivity in mice as measured by spontaneous locomotor activity (Frieriksson et al., 
1990; Nishi et a l, 1991).
4.2. Locomotor Characterisation of the AS/AGU Rat
The initial characterisation of the AS/AGU rat involved the use of a number of 
locomotor tests base on those in Marshall & Teitelbaum (1974), in order to find out which 
would provide the simplest and most effective means by which to quantitate the differences 
between mutants and the parent AS strain. Tests which required the animal to grip and 
hang onto metal bars were not of any value as the forelimbs seem to be relatively 
unaffected in the mutant. An open field test whereby the rat is placed in the centre of a fiat 
Perspex sheet with concentric, evenly spaced rings to measure distance travelled, was
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intended as a test of initiation of movement and time taken to travel short distances. 
Although some interesting observations were made, with AS/AGU rats taking longer to 
initiate movement, this was not consistent. The conditions under which the test had to be 
carried out, i.e., a novel environment, were such that stress and mood probably had an 
influence on behaviour in this task. A stepping test, whereby the rat’s forelimbs were 
placed on a polystyrene step with animals having to lift their hind limbs onto the step, also 
proved inconsistent despite the obvious effects of the mutation on hind limbs. Inclined 
ramp, mid-air righting, spontaneous locomotor activity and gait analysis were chosen as 
being the most consistent, robust and reliable means by which to characterise and measure 
the locomotor deficits in the AS/AGU rat.
4.3. The Effects of Age on Locomotor Behaviour in the AS/AGU Rat
Inclined ramp and mid-air righting tests quickly established differences in abilities 
between AS/AGU and control animals. Payne and colleagues (1998) reported data for these 
tests with 6  month old rats which showed significant differences between mutants and 
controls in both tests.
4.3.1. Inclined Ramp Test
The testing conditions for mid-air righting in previous AS/AGU work were the 
same as with the present study. The inclined ramp test, however, differed in that previously 
only one ramp (13cm) was used (Payne et a l, 1998). This single ramp established a clear 
difference in performance between the two groups. The animals earlier investigations did 
not vary much in size, and the chosen ramp width was appropriate for the size of the 
animal As the purpose of the present work was to study the progressive nature of the 
disorder at various age points at which both body size and locomotor ability might change,
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a series of ramps of different widths was felt necessary. Thus, it should be possible to test a 
rat of any size, within the age range, on a ramp that most suited its size and gait width, and 
to test also on ramps that would present a range of increasingly difficult challenges. Rats 
could thus be assessed also on their ability to adjust their gait width in a controlled manner 
in order to negotiate ramps which were narrower than this.
As can be expected, noimal control rats are generally successful on a range of ramp 
widths. In the vast majority of cases, AS rats can comfortably walk down ramps of any 
width used in this study. Bigger, heavier control animals in the oldest age groups (5 months 
and above) tended to struggle, however, with the narrowest (1cm) ramp used. These rats 
seemed able to adjust their gait Avidth to the width of the ramp, but were inhibited by their 
size and weight.
The choice of ramp widths used in this study proved successful in demonstrating 
the progressive nature of the mutant’s movement disorder. Thus, poor general performance 
rates by AS/AGU rats was manifested by (for example) a) no mutant of any age being able 
to negotiate the narrowest ( 1cm) ramp, and b) none of the oldest animals being able to 
negotiate any ramp except the broadest. The physical features of the locomotor impairment 
itself may serve as the main reasons for the general lack of success:
• A wide gait makes it difficult for a mutant to walk down a ramp unless that 
ramp is of a width that is much broader than the gait width, as observed when 
the animal is first placed on the ramp. AS/AGU animals seem unable to adjust 
gait width in a controlled manner in order to negotiate ramps that are narrower 
than the natural splay of their hind limbs.
• Having difficulty in initiating movement, particularly with older animals, 
mutants often eventually set off in an uncontrolled manner, resulting in their
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falling off near the top of the ramp. Occasionally this latency can result in the 
rat falling off as soon as it attempts to move.
• The staggering nature of movement in the mutant renders the rat unable to 
recover balance on a ramp unless that ramp is much broader than the width of 
the animal’s body. This results in the animal falling off after a few strides down 
the ramp.
• As the worst affected animals fall over every few steps when walking on a flat 
surface, animals are generally unable to remain on ramps of any width after a 
small number of steps.
4.3.2. Mid-Air Righting
The study of the righting reflex in mid-air provided a robust test which 
demonstrated a clear difference in ability between control and mutant groups (Payne et al., 
1998). The air-righting reflex consists of a chain of events that occur after a rat is released 
in mid-air. Initial labyrinthine stimulation triggers rotation of the shoulders, which carry 
the head and neck around also. Cervical righting reflex then moves the lower end of the 
body round in tandem with the forelimbs, resulting in a horizontal position which is 
achieved very quickly, allowing the rat to land on all four limbs comfortably (Pellis et al., 
1991). Rats are able to right in mid-air successfully at about age 16 days postnatal (Hard 
and Larsson, 1975).
A minority of the oldest AS control animals in this study (1 year old rats, which are 
also the largest and heaviest) failed to right in mid-air, but all other age groups showed 
complete or almost complete success. This provided an ideal basis for comparison with 
mutant animals. AS/AGU rats showed an obvious inability in this test from the earliest age 
tested. Whether or not the rat lands on its feet after mid-air righting is normally a clean cut
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observation. When a control animal is held upside down until relaxed, and dropped, it 
turns 180 degrees instantly and lands comfortably on all fours. AS/AGU animals do not 
display such slick movement, and show varying patterns when dropped, such as a) 
completely failing to turn and landing flatly on their backs, b) turning only either hind or 
forelimbs and landing on their sides or c) turning too far and landing heavily on the 
bedding layer. These awkward patterns normally result in animals landing either on their 
back, side, head or tail. It is possible that different patterns may emerge as the animals get 
older. It was observed as the animals were dropped that the one year old mutants failed to 
turn to any degree, and landed directly upside down more frequently than younger age 
groups.
When a rat is held upside down and dropped, its first reaction is to turn immediately 
through 180 degrees in order to land on its feet. It is likely that, although this inclination is 
present in AS/AGU rats (a reasonable number up to the age of 3 months land on their feet), 
it is the varying degree of disability which renders the mutants unable to move their body 
in line with this ‘desire’ to turn and land safely on all foui's. This may make mutants less 
able to initiate the air righting sequence than normal control animals. There is no evidence 
to suggest that mutants lack the motivation to turn.
4.3.3. Gait Analvsis
The use of a footfall chamber and an image analysis macro program, for the close study of 
footfall patterns, was successful in achieving its aim. It was possible to quantitate the 
pattern of weight distribution in the lateral-medial plane in the AS/AGU rat and to compare 
it with that of AS controls. In AS animals, the distribution of pressure on the footpads is 
evenly distributed along a line passing down the centre of the foot, whereas in AS/AGU 
rats pressure is often concentrated on either the medial or lateral side. When all of the
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footfalls from all of the animals tested are shown together in a scatter diagram (Figure 3), 
mutant weight distribution is much more widely scattered than that of controls and about 
40% of AS/AGU footfalls lie outwith two standard deviations of the mean for AS control 
values. Moreover, AS/AGU footfalls that lie outwith the normal AS range are evenly 
distributed between those falling heavily on the lateral side of the foot, and those which 
show excessive medial contact. This pattern of distribution is what you might expect with a 
rat that walks in an ungainly manner with a staggering gait. When a mutant rat leans 
excessively on one side, lateral foot-floor contact is generally excessive on that side with 
percentage lateral pad contact being increased (and the medial contact decreased) as the rat 
leans further. As the animal’s weight swings across to the other side, the same pattern is 
repeated for that side. This, however, was not always the case due to the fact that 
occasionally the weight bearing foot would be placed so awkwardly on the walking surface 
during motion that it would have uniform, or even excessive, medial, pad contact. On 
those occasions, the rat was more likely to slow down and stop walking, or to fall over by 
tripping on the awkward foot.
4.3.4. Infrared Movement Analvsis
Spontaneous locomotor activity in a cage environment was found to be increased in 
both short (12-minute) and long (2 2 -hour) sessions, and significantly so during the longer 
sessions.
AS/AGU rats eat, drink and groom normally (Clarke and Payne, 1994), activities 
that would normally cause the animal to register small and large movements with this 
apparatus. During the 12-minute sessions, it is possible that mutant rats do not settle as 
quickly as AS controls in an unfamiliar cage, which is larger and deeper than their normal
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cage environment. Normal sized cages could not be used during this experiment because 
the optimised use of the infrared sensors required a larger cage.
With the 22-hour sessions, however, this is less likely to be the case. It was not practical to 
observe the rats during these sessions and so the exact nature of movements is unknown 
over a day-long session part of which covers a dark period during which rats are naturally 
more active. It is possible that grooming, for example, occurs more regularly in the 
AS/AGU rats or lasts longer during this period. Limitations of the infrared activity 
apparatus such as the inability to record the speed, direction or type of movements, or the 
relatively crude time parameter options, make it difficult to determine whether tremor in 
the mutant rat is detected by the sensors. With the mutant rat being significantly more 
active than controls during the longer sessions, there is the possibility that tremor is being 
detected.
These data confirm that the AS/AGU rat, although showing signs of locomotor 
disability and having neurochemical deficits, is still active enough to be used in locomotor 
testing.
4.4. L-DOPA Replacement
Locomotor deficits in the AS/AGU rat seem likely to aiise mainly from deficits in 
the dopaminergic system, in particular the heavy loss of available neurotransmitter in the 
striatum, with reductions of up to 80% in extracellular fluid at 3 months of age and beyond 
(Campbell et al., 1998), and 30% reductions in striatal whole tissue levels from 6  months. 
In light of this, the efficacy of L-DOPA, a dopamine precursor, in ameliorating the 
resulting locomotor symptoms is not an unexpected occurrence.
Improvements in performance when L-DOPA treated AS/AGU animals were tested 
on inclined ramp and mid-air righting tests could be attributed to a general overall
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improvement in motor ability. They seemed more willing to initiate and more able to 
execute movement. In the mid-air righting test, it is thus possible that the mutant rat was 
more able to rotate its body in accordance with vestibular stimulus than untreated animals. 
This ability improved as the chronic treatment progressed. Similarly, in the inclined ramp 
test, mutants would have been able to walk down ramps, and to adjust gait width, in a more 
controlled manner in order to negotiate narrower ramps than their untreated counterparts. 
4.4.1. Pharmacokinetics
It is supposed that, although L-DOPA is itself proposed to be a neurotransmitter, 
having pre- and post-synaptic responses (Misu et al., 1996), in order to be effective in 
improving locomotor responses, L-DOPA must firstly be converted to dopamine in the 
striatum by the enzyme L-aromatic amino acid decarboxylase (L-AAAD). Newly 
synthesized dopamine must then be released and interact with striatal dopamine receptors 
to produce an effect. The amount of LAAAD influences the rate of this process by 
controlling the amount of dopamine produced by exogenous L-DOPA. This whole process, 
from L-DOPA administration through to it producing chemical and physical effects, is 
thought to take between 45 and 90 minutes to complete (Shoulson et al., 1975).
The time course from L-DOPA administration to dopamine release is slower in the 
AS/AGU rat as compared to AS control (see Figure 12a); it takes 120 minutes for a peak 
level of dopamine to be achieved compared with 80 minutes in the control animal. 
Although we have no information on this, it could be a reflection of the amount of L- 
AAAD available to the administered L-DOPA in mutants, with conversion to dopamine 
being delayed. In this connection, reductions in L-AAAD have been found in both 
Parkinson’s disease and 6 -hydroxy dopamine lesioned rats (Wooten, 1987).
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After 4 week administration of 25mg/kg L-DOPA, resting levels of extracellular dopamine 
were approximately doubled in both AS controls and AS/AGU mutant rats compared to 
untreated controls. However, after the administration of lOOmg/kg of L-DOPA by a bolus
I.P. injection, mutants showed a higher percentage rise in extracellular DA levels, 
compared with resting levels, than the controls. This was the case both with average and 
peak post-bolus values. Absolute levels, however, remained lower in the AS/AGU than in 
the mutant.
In a study on the effects of L-DOPA on normal and 6 -hydroxy dopamine lesioned 
rats, Abercrombie and colleagues (1990) suggested that i) low doses of L-DOPA enhance 
the storage pool of dopamine in dopaminergic neurons making it susceptible mainly to 
normal impulse evoked release whereas ii) higher doses of the drug cause leakage of 
dopamine from synaptic vesicles directly into the extracellular fluid. Hence, dopamine 
formed from exogenous L-DOPA (lOOmg/kg) in 6 -OHDA treated rats is released in an 
impulse independent manner rather than being stored in vesicles for subsequent release, 
and this mechanism along with lesion induced loss of re-uptake sites is responsible for the 
shaip increase in extracellular dopamine levels.
It is possible that this hypothesis may apply in the present study and that the 
25mg/kg dose is increasing dopamine stores, and therefore effecting a lower release rate in 
AS/AGU animals compared with controls. In order to elucidate this further, it would be 
worthwhile studying the same L-DOPA doses as in this study, combined with a re-uptake 
inhibitor such as nomifensine. This may show whether a possible reduction in dopamine 
re-uptake is also a factor in the pharmacokinetics of the lOOmg/kg dose. Campbell and 
colleagues (2000) reported that after nomifensine administration, AS/AGU rats showed a 
much smaller drug induced increase in extracellular dopamine levels (due to re-uptake 
inhibition) than AS controls. This confirms that under normal conditions, synaptic release
69
in the mutant is low, and demonstrates that re-uptake differences do not underlie the 
release problem.
Higher extracellular dopamine rises relative to basal and L-DOPA resting levels in 
AS/AGU compared with AS controls may also reflect quicker penetration of dopamine into 
neurons in the mutant. These neurons may have a greater capacity for dopamine influx due 
to a natural deficit. This may explain the higher percentage rise in post-bolus DOPAC and 
HVA levels in the mutant extracellular fluid, as compared with control levels. Moreover, if 
normal AS cells and terminals are packed with a large influx of dopamine, which would 
not normally exist, they may struggle to cope with this due to increases over normal 
capacity.
4.5. The AS/AGU Rat as a Model for a Movement Disorder
The inclined ramp and mid-air righting tests employed in this study were successful 
as simple, consistent and reproducible methods. They were thus important and useful in 
the characterisation and measurement of the locomotor disorder due to the AS/AGU 
mutation, and in confirming its progressive nature . The use of a footfall chamber in 
studying footfall patterns was both an interesting and dynamic technique which showed a 
dramatic difference between mutant and parent strains. This was, however, a complex and 
time consuming method which gave a relatively small amount of information. The infrared 
movement system, a widely used method in the field of locomotor study, was confirmed as 
a valuable tool in this study.
The use of L-DOPA, as a method of replacing dopamine in deficient mutants, was 
successful in both enabling the mutants to perform more effectively under testing 
conditions, and also in increasing extracellular dopamine levels in the striatum.
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In terms of the genetic component of this animal model, a loss of PKC-y may 
explain some of the neurological dysfunction present. Although PKC-y is not involved 
exclusively in the packaging and release of neurotransmitters from vesicles, it may still 
play an integral role in these processes (Chen et al., 1995). This is because other types of 
PKC (PKC alpha and beta) may be up-regulated as a result of PKC-y deficiency using 
cellular compensatory mechanisms. Therefore loss of PKC-y in the AS/AGU rat may partly 
explain why the neurotransmitter release mechanism seems to be affected in these animals.
In summary, the AS/AGU rat model is indeed an excellent model for a movement 
disorder. Both the known characteristics, and those yet to be discovered, make this a 
valuable testing ground for potential drug treatments for Parkinson-like diseases.
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CONCLUSIONS
CONCLUSIONS
Although the use of toxin- and lesion-induced models of basal ganglia based 
movement disorders has long been of significant benefit to the understanding of the 
aetiology of diseases such as Parkinson’s Disease and Huntington’s Disease, and has also 
advanced the knowledge and understanding of basal ganglia circuitry and function, these 
models have intrinsic limitations. Such models, although producing relevant disease 
characteristics, are generally transient in nature with significant recovery being a feature of 
certain methods. Lesions can be non-specific, affecting also neurotransmitters not directly 
related to the area of study. Furthermore, with induced models, progression of disease 
cannot be measured from a young age through to an advanced state at older ages.
Models that show a movement disorder as the result of a mutation have 
potential advantages over toxic models whilst retaining many of the useful features of these 
animals. In the AS/AGU mutant, which seems to be unique in having no obvious cerebellar 
dysfunction, symptoms are detectable at a very young age. There is the advantage with this 
mutant of studying the natural progression of both the chemical and physical deficits 
present in this innate condition. Its genetic nature may offer insight into the genetic aspects 
of basal ganglia disease. There is, for example, the opportunity to study the possible 
connection between PKC-y and Parkinson-like symptoms, in terms of cell function and 
synaptic release.
Improvements, both physical and chemical, as a result of L-DOPA replacement in 
the AS/AGU rat mirror those in patients with Parkinson’s disease. It would be interesting 
to study the effects of L-DOPA over a longer time period with the mutant rat, in order to 
assess whether the detrimental effects due to prolonged use in humans occur in this rat. 
This would also present the possibility of testing other drugs alongside L-DOPA which
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may reduce these side effects. This potentially important model could, in future, be used as 
a testing ground for drugs such as dopamine agonists, MAO inhibitors or specific PKC 
drugs.
Future work might include closer study of enzymes such as MAO and L-AAAD; 
investigations into other components of the basal ganglia such as STN or GP; gaining 
more knowledge of other dopaminergic areas including the hypothalamus and the olfactory 
system; or the study of dopamine receptors, in the AS/AGU rat.
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APPENDICES
APPENDIX 1
Method for calculating neurotransmitter concentrations as measured by HPLC peak 
areas
A response factor (RF), the ratio of the peak areas of the amine of interest and the internal 
standard, is firstly calculated from the peaks in the composite standard.
Thus:
Area of Internal Standard in Composite Standard
Response Factor = ---------------------------------------------------------------
Area of Amine in Composite Standard
This RF is then applied to a second calculation in order to determine the absolute value of 
neurotransmitter in the sample. This is repeated for each neurotransmitter found in the 
sample.
Area of Amine in Sample
Peak Concentration = ------------------------------------------------ x RF x 1.11x10'^ mg/pl
Area of Internal Standard in Sample
The figure of 1.11 x 10‘^  is a conversion factor based on the known concentrations of the 
internal standard in the composite, and to account for the DHBA concentration in the 
sample.
Final Concentrations are expressed as picograms per sample.
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APPENDIX 2
Chemicals and Equipment Used in this Studiy.
Antec INTRO Electrochemical Detector Presearch Limited, System House, 59-61 Knowl 
Piece, Hitchin, Herts., SG4 OTY, UK.
Antisedan latipamezole hvdrochloridel Pifzer UK Ltd., Canada House, 272 Field End 
Road, Eastcote, Ruislip, Middlesex, HA4 9NA, UK.
CMA Automatic Microiniector (microdialvsis) Biotech Instruments, Biotech House, 75 A 
High Street, Kimpton, Herts., SG$ 8PU, UK.
Drugs and Composite Standard Components
L-Dopa, Benserazide, DHBA, Dopamine, DOPAC, 5HT, 5HIAA, HVA. 
Sigma-Aldrich Ltd., Fancy Road, Poole, Dorset, BH12 4NZ, UK.
HPLC Equipment
Gilson 305 Pump, 805 Manometric Module, 71251 Rheodyne sample injector, 
microbore colum.
Anachem Ltd., 20 Charles Street, Luton, UK.
Infra-red Motion Activity System Coulbum Instruments, 7462 Penn Drive, Allentown, PA 
18108, USA.
Jeol Crvoststat Leica Microsystems (UK) Ltd., Davy Avenue, Knowlhill, Milton Keynes, 
MK5 8LB, UK.
Kontron KS400 Image Analysis System Imaging Associates Ltd., Thame Business Park, 
Wenman Road, Thame, Oxford, 0X 9 3XA, UK.
Kopf Stereotaxic Frame David Kopf Instruments, 7234 Elmo Street, Tujunga, CA, 91042 
USA.
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Mobile Phase Components
Citric Acid, EDTA, Disodium Hydrogen Phosphate, Octane Sulphonic Acid, Methanol. 
Sodium Bisulphite. Sigma-Aldrich Ltd., Fancy Road, Poole, Dorset, BH12 4NZ, UK.
Redifast dental cement liquid Wright Health Group Ltd., Dundee, UK.
Rompun tXvlazine hydrochloride) Bayer Pic., Bayer House, Strawberry Hill, Newbury, 
Berkshire, RG14 1JA, UK.
RS epoxy resin RS Components, PO Box 99Corby, Northhants, NN17 9RS. UK
Silicon Graphics Computer and Software SGI Ltd., 1530 Arlington Business Park, Theale, 
Reading, Berkshire, RG7 4SB, UK.
Sony Handicam Video camera Sony UK Ltd., Brooklands, Weybridge, Surrey, UK.
Tubing for Probe Construction RJ Woods, 39 Blavk Sneddon Street, Paisley, PA3 2DE, 
UK.
Vetalar (ketamine hydrochloride) Pharmacia & Upjohn Ltd (Animal Health), Hunters 
Road, Weldon North Estate, Corby, Northants, NN17 5 JE, UK.
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APPENDIX 3
Appendix 3a. Analyses of variance for performance in Inclined Ramp Test for il AS and 
ii) AS/AGU rats at different ages. Each Figure shows the relevant analysis of variance (FI 
together with the means and 95% confidence intervals displayed pictorially. Age groups 
differ if the confidence intervals do not overlap
AS rats
ANALYSIS OF VARIANCE
SOURCE DF SS MS F p
FACTOR 5 2 4 . 3 4 0 4 . 8 6 8 3 3 . 2 3  < 0 . 0 0 1
ERROR
TOTAL
158
1 6 3
2 3 . 1 4 7
4 7 . 4 8 8
0 . 1 4 7
INDIVIDUAL 95% Cl'S FOR MEAN 
BASED ON POOLED STDEV
AGE N MEAN ST DEV ----------------- + ------------------- + -------------------+ ------
2 0 - 3 0 17 1 . 0 0 0 0 0 .  0 0 0 0 ( --------* -------- )
4 0 - 5 0 35 1 . 0 5 7 1 0 . 2 3 5 5 ( —  * ----- )
6 0 - 7 0 37 1 . 0 2 7 0 0 . 1 6 4 4 ( - - * — )
1 0 0 - 1 3 0 34 1 . 4 7 0 6 0 . 6 1 4 7 ( — * - - )
1 4 0 - 1 5 0 22 1 . 9 0 9 1 0 . 4 2 6 4 Ç----- * ------ J
3 6 5 19 2 . 0 0 0 0 0 . 4 7 1 4
1 . 2 0  1 . 6 0 2 . 0 0
AS/AGU rats
ANALYSIS OF VARIANCE
SOURCE DF SS MS F p
FACTOR 5 2 0 3 . 3 6 4 0 . 6 7 3 5 . 1 7  < 0 . 0 0 1
ERROR
TOTAL
1 2 9
134
1 4 9 . 1 9
3 5 2 . 5 5
1 . 1 6
INDIVIDUAL 95% Cl'S FOR MEAN 
BASED ON POOLED STDEV
LEVEL N MEAN STDEV + + +
2 0 - 3 0 17 2 . 7 0 6 0 .  6 8 6 ( —  *  —  )
4 0 - 5 0 27 3 . 5 9 3 1 . 1 8 5  ^ ^
6 0 - 7 0 24 4 . 6 2 5 0 . 8 7 5 ( - - *  —  )
1 0 0 - 1 3 0 27 5 . 4 0 7 1 . 3 9 4  ^  ^ ^
1 4 0 - 1 5 0 20 4 . 9 0 0 1 . 3 3 4 ( ----- * —  )
3 6 5 20 6 . 8 0 0 0 .  4 1 0 (
3 . 0 4 . 5 6 . 0
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Appendix 3b. Comparisons of the performance on the Inclined Ramp test of AS and 
AS/AGU rats at the ages shown. The tests performed were student's t-tests and all tests 
assume a two-tailed distribution.
AS 3 0 - 4 0  
AGO 3 0 - 4 0
AS 6 0 - 7 0  
AGO 6 0 - 7 0
N MEAN STDEV
35 1 . 0 5 7 0 . 2 3 6
27 3 . 5 9 1 . 1 9
P < 0 . 0 0 1  DF= 27
N MEAN STDEV
37 1 . 0 2 7 0 . 1 6 4
24 4 . 6 2 5 0 . 8 7 5
P < 0 . 0 0 1  DF= 24
SE MEAN 
0 . 0 4 0  
0 . 2 3
SE MEAN 
0 .  027  
0 . 1 8
N MEAN STDEV SE MEAN
AS 1 0 0 - 1 3 0 34 1 .  4 7 1 0 . 6 1 5 0 . 1 1
AGU 1 0 0 - 1 3 0 27 5 . 4 1 1 . 3 9 0 . 2 7
T -  - ■ 1 3 . 6 6  P < 0 . 0 0 1 DF= 34
N MEAN STDEV SE MEAN
AS 1 4 0 - 1 5 0 22 1 . 9 0 9 0 . 4 2 6 0 . 0 9 1
AGU 1 4 0 - 1 5 0 20 4 . 90 1 . 3 3 0 . 3 0
T= - 9 . 5 9  P < 0 . 0 0 1  DF= 22
N MEAN STDEV
AS 3 6 5 19 2 . 0 0 0 0 . 4 7 1
AGU 3 6 5 20 6 . 8 0 0 0 . 4 1 0
T -  - 3 3 . 8 4 P < 0 . 0 0 1  DF- 35
SE MEAN 
0 . 1 1  
0 . 0 9 2
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APPENDIX 4
Age AS AS/AGU t - df P
Turned Fell Turned Fell
20-30 17 0 10 7 6.48 1 <0.05
40-50 35 0 14 13 18.52 1 <0.001
60-70 34 3 9 15 18.17 1 <0.001
80-90 23 0 17 22 17.72 1 < 0.001
100-130 34 0 11 16 24.36 1 < 0.001
140-150 21 1 4 16 21.72 1 <0.001
365 13 6 0 20 17.56 1 <0.001
S8
APPENDIX 5
Comparisons between gait analysis data for AS and AS/AGU male rats. Comparisons are 
made by Student's t-test between the two groups for a) the best recorded footfall b) the 
worst recorded footfall and c) the difference between the best and worst recorded footfalls. 
In each case, a "perfect" footfall is held to be one where weight distribution averaged over 
the period of contact is 50% on each side of the mid-line.
a) The best recorded footfall
N MEAN STDEV SE MEAN
AS best 8 1.44 1.87 0.66
AGU best 7 3.10 5.33 2.0
T= -0.78 P=0.4 6 DF= 7
b) The worst recorded footfall
N
AS worst 8 
AGO worst 7
MEAN
1 1 . 0
24.8
STDEV
10.3
1 1 . 2
T= -2.47 P=0.029 DF= 12
c) Best minus worst recorded footfall
AS b-w 
AGU b-w
MEAN
11.83
2 2 . 6 8
STDEV
9.58
7.65
SE MEAN 
3.7 
4.2
SE MEAN 
3.4 
2.9
T= -2.44 P=0.031 DF= 12
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APPENDIX 6
Comparisons were made between both 9 month and 12 month male AS and AS/AGU rats 
for both small and large movements, in both 12-minute and 22-hour sessions.
Comparisons were made using Student’s t-tests.
12-minute sessions (9 month animals)
(a) Small movements
Two sample T for Cl vs C2
N Mean StDev SE Mean
AS 12 18.7 12.1 3.5
AS/AGU 10 27.5 13.3 4.2
95% Cl for mu Cl - mu C2: ( -20.3, 2.7)
T-Test mu Cl = mu C2 (vs not =): T = -1.62 P = 0.12 DF = 18
( b ) Large movements
Two sample T for C3 vs C4
N Mean StDev SE Mean
AS 12 6.00 6.52 1.9
AS/AGU 10 10.70 7.04 2.2
95% Cl for mu C3 - mu C4: ( -10.8, 1.4)
T-Test mu C3 = mu C4 (vs not =): T = -1.61 P = 0.12 DF = 18
12-minute sessions (12 month animals)
(a) small movements
Two sample T for C5 vs C6
N Mean StDev SE Mean
AS 11 17.8 14.2 4.3
AS/AGU 10 23.6 18.8 5.9
95% Cl for mu C5 - mu C6: ( -21.3, 9.7)
T-Test mu C5 = mu C6 (vs not =): T = -0.79 P = 0.44 DF = 16
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(b) Large movements
N Mean StDev SE Mean
AS 11 2.45 3.52 1.1
AS/AGU 0 8.9 10.7 3.4
95% CI for mu C7 - mu C8: ( -14.3, 1.4)
T-Test mu Cl = mu C8 (vs not =); T = -1.82 P = 0.099 DF = 10
22-hour sessions (9 month animals)
(a) Small movements
N Mean StDev SE Mean
AS 10 628 136 43
AS/AGU 8 978 376 133
95% CI for mu Cl - mu C2: ( -672, -28)
T-Test mu Cl = mu C2 {vs not =): T = -2.50 P = 0.037 DF
(b) Large movements
N Mean StDev SE Mean
AS 10 104.0 35.7 11
AS/AGU 8 206.1 85.1 30
95% Cl for mu C3 - mu C4: ( -176, -28)
T-Test mu C3 = mu C4 (vs not =): T = -3.18 P = 0.013 DF
22-hour sessions (12 month animals)
(a) Small movements
N Mean StDev SE Mean
AS 11 544 189 57
AS/AGU 9 1059 259 86
95% Cl for mu C5 - mu C6: (-737, -294)
T-Test mu C5 = mu C6 (vs not =): T = -4.98 P = 0.0002 DF = 14
(b) Large movements
Two sample T for Cl vs C8
N Mean StDev SE Mean
AS 11 86.7 44.6 13
AS/AGU 9 235.3 83.4 28
95% Cl for mu Cl - mu C8 : ( -217, -81)
T-Test mu Cl = mu C8 (vs not =): T = -4.81 P = 0.0005 DF — 11
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APPENDIX 7
Appendix 7 (a) Two-way analysis of variance comparing treatment (saline v. L-DOPA) and 
week of treatment (week 3 v. week 4) for the performance of AS/AGU rats in the Inclined 
Ramp test. This shows a significant variance for both treatment and week of treatment
SOURCE DF SS MS F P
week 1 11.02 11.02 7.39 < 0.001
treatment 1 18.23 18.23 12.23 < 0.001
INTERACTION 1 2.03 2.03 1.36 ns
ERROR 36 53.70 1.49
TOTAL 39 84.97
Appendix 7 (b) Comparisons of performance in the Inclined Ramp test of AS/AGU rats 
treated with L-DOPA (25mg/kg) or saline i) on week 3 of treatment, ii) on week 4 of 
treatment. From this it will be seen that differences in performance are not significant by 
week 3, but are significant by week 4.
i) Week 3 of treatment
N MEAN STDEV SE MEAN
L- DOPA 10 5.30 1.49 0.47
Saline 10 6.20 1.03 0.33
T= -1.57 P=0.14 DF= 16
ii) Week 4 
N
L-DOPA 10 
Saline 10
of treatment
MEAN STDEV SE MEAN
3.80 1.32 0.42
5.60 0.96 0.31
T= -3.49 P=0.0031 DF= 16
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APPENDIX 8
The numbers of AS/AGU animals treated with daily injections of saline or L-DOPA 
(25mg/kg) which can successfully right themselves in mid-air after being held upside down 
and dropped from 50 cm above a soft landing. Tests were carried out weekly.
Week Saline L-DOPA df P
1 3/10 2/10 0.20 1 ns
2 2/10 5/10 1.28 1 ^ ns
3 0/10 8/10 8 1 <0.01
4 0/10 9/10 9 1 <0.01
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